

alberico Catapano

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6029089/publications.pdf>

Version: 2024-02-01

640
papers

65,835
citations

2802

94
h-index

947

239
g-index

683
all docs

683
docs citations

683
times ranked

50794
citing authors

#	ARTICLE	IF	CITATIONS
1	2016 European Guidelines on cardiovascular disease prevention in clinical practice. <i>European Heart Journal</i> , 2016, 37, 2315-2381.	2.2	5,370
2	2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. <i>European Heart Journal</i> , 2020, 41, 111-188.	2.2	4,871
3	Global Burden of Cardiovascular Diseases and Risk Factors, 1990â€“2019. <i>Journal of the American College of Cardiology</i> , 2020, 76, 2982-3021.	2.8	4,468
4	ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). <i>European Heart Journal</i> , 2011, 32, 1769-1818.	2.2	2,767
5	2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. <i>European Heart Journal</i> , 2016, 37, 2999-3058.	2.2	2,393
6	Global, regional, and national burden of stroke and its risk factors, 1990â€“2019: a systematic analysis for the Global Burden of Disease Study 2019. <i>Lancet Neurology</i> , The, 2021, 20, 795-820.	10.2	2,308
7	Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. <i>European Heart Journal</i> , 2017, 38, 2459-2472.	2.2	2,292
8	Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: Consensus Statement of the European Atherosclerosis Society. <i>European Heart Journal</i> , 2013, 34, 3478-3490.	2.2	2,132
9	2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. <i>Atherosclerosis</i> , 2019, 290, 140-205.	0.8	1,753
10	Lipoprotein(a) as a cardiovascular risk factor: current status. <i>European Heart Journal</i> , 2010, 31, 2844-2853.	2.2	1,392
11	2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. <i>Atherosclerosis</i> , 2016, 253, 281-344.	0.8	1,189
12	Statin-associated muscle symptoms: impact on statin therapyâ€”European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. <i>European Heart Journal</i> , 2015, 36, 1012-1022.	2.2	1,024
13	Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. <i>European Heart Journal</i> , 2011, 32, 1345-1361.	2.2	993
14	Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. <i>European Heart Journal</i> , 2014, 35, 2146-2157.	2.2	835
15	Identification of seven loci affecting mean telomere length and their association with disease. <i>Nature Genetics</i> , 2013, 45, 422-427.	21.4	808
16	Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel. <i>European Heart Journal</i> , 2020, 41, 2313-2330.	2.2	776
17	2016 European Guidelines on cardiovascular disease prevention in clinical practice. <i>European Journal of Preventive Cardiology</i> , 2016, 23, NP1-NP96.	1.8	683
18	Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment. <i>European Heart Journal</i> , 2015, 36, 2425-2437.	2.2	644

#	ARTICLE	IF	CITATIONS
19	Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes. New England Journal of Medicine, 2016, 375, 2144-2153.	27.0	596
20	ESC/EAS Guidelines for the management of dyslipidaemias. Atherosclerosis, 2011, 217, 3-46.	0.8	561
21	LOX-1, OxLDL, and Atherosclerosis. Mediators of Inflammation, 2013, 2013, 1-12.	3.0	548
22	Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol. New England Journal of Medicine, 2019, 380, 1022-1032.	27.0	529
23	High-Density Lipoprotein Subfractions - What the Clinicians Need to Know. Cardiology, 2013, 124, 116-125.	1.4	509
24	Carotid intima-media thickness progression to predict cardiovascular events in the general population (the PROG-IMT collaborative project): a meta-analysis of individual participant data. Lancet, The, 2012, 379, 2053-2062.	13.7	506
25	The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management. Lancet Diabetes and Endocrinology, the, 2014, 2, 655-666.	11.4	473
26	Association of Triglyceride-Lowering LPL Variants and LDL-C "Lowering LDLR Variants With Risk of Coronary Heart Disease. JAMA - Journal of the American Medical Association, 2019, 321, 364.	7.4	460
27	From endothelial dysfunction to atherosclerosis. Autoimmunity Reviews, 2010, 9, 830-834.	5.8	432
28	Plant sterols and plant stanols in the management of dyslipidaemia and prevention of cardiovascular disease. Atherosclerosis, 2014, 232, 346-360.	0.8	419
29	2016 European Guidelines on cardiovascular disease prevention in clinical practice. Atherosclerosis, 2016, 252, 207-274.	0.8	415
30	EU-Wide Cross-Sectional Observational Study of Lipid-Modifying Therapy Use in Secondary and Primary Care: the DA VINCI study. European Journal of Preventive Cardiology, 2021, 28, 1279-1289.	1.8	369
31	Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel. Lancet Diabetes and Endocrinology, the, 2016, 4, 850-861.	11.4	329
32	Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies "a consensus statement from the European Atherosclerosis Society. European Heart Journal, 2021, 42, 4791-4806.	2.2	303
33	Apolipoprotein B Particles and Cardiovascular Disease. JAMA Cardiology, 2019, 4, 1287.	6.1	299
34	Global epidemiology of dyslipidaemias. Nature Reviews Cardiology, 2021, 18, 689-700.	13.7	290
35	Impact of Lipids on Cardiovascular Health. Journal of the American College of Cardiology, 2018, 72, 1141-1156.	2.8	272
36	The ACC/AHA 2013 guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: the good the bad and the uncertain: a comparison with ESC/EAS guidelines for the management of dyslipidaemias 2011. European Heart Journal, 2014, 35, 960-968.	2.2	270

#	ARTICLE	IF	CITATIONS
37	Adverse effects of statin therapy: perception vs. the evidence – focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract. <i>European Heart Journal</i> , 2018, 39, 2526-2539.	2.2	262
38	Deficiency of the Long Pentraxin PTX3 Promotes Vascular Inflammation and Atherosclerosis. <i>Circulation</i> , 2009, 120, 699-708.	1.6	252
39	Association of Genetic Variants Related to CETP Inhibitors and Statins With Lipoprotein Levels and Cardiovascular Risk. <i>JAMA - Journal of the American Medical Association</i> , 2017, 318, 947.	7.4	247
40	HDL in innate and adaptive immunity. <i>Cardiovascular Research</i> , 2014, 103, 372-383.	3.8	236
41	Cancer Risk Associated with Use of Metformin and Sulfonylurea in Type 2 Diabetes: A Meta-Analysis. <i>Oncologist</i> , 2012, 17, 813-822.	3.7	233
42	Berberine, a plant alkaloid with lipid- and glucose-lowering properties: From in vitro evidence to clinical studies. <i>Atherosclerosis</i> , 2015, 243, 449-461.	0.8	231
43	Pharmacology of competitive inhibitors of HMG-CoA reductase. <i>Pharmacological Research</i> , 1995, 31, 9-27.	7.1	225
44	Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy. <i>European Journal of Preventive Cardiology</i> , 2020, 27, 593-603.	1.8	224
45	Mendelian Randomization Study of <i>ACLY</i> and Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2019, 380, 1033-1042.	27.0	216
46	Dietary linoleic acid and human health: Focus on cardiovascular and cardiometabolic effects. <i>Atherosclerosis</i> , 2020, 292, 90-98.	0.8	213
47	Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels. <i>Atherosclerosis</i> , 2012, 220, 381-386.	0.8	212
48	2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. <i>Russian Journal of Cardiology</i> , 2020, 25, 3826.	1.4	199
49	Carotid Artery Intima-media Thickness in Nonalcoholic Fatty Liver Disease. <i>American Journal of Medicine</i> , 2008, 121, 72-78.	1.5	189
50	Quantifying Atherogenic Lipoproteins: Current and Future Challenges in the Era of Personalized Medicine and Very Low Concentrations of LDL Cholesterol. A Consensus Statement from EAS and EFLM. <i>Clinical Chemistry</i> , 2018, 64, 1006-1033.	3.2	189
51	Regulatory T Cell Migration Is Dependent on Glucokinase-Mediated Glycolysis. <i>Immunity</i> , 2017, 47, 875-889.e10.	14.3	181
52	ESC/EAS Guidelines for the management of dyslipidaemias. <i>Atherosclerosis</i> , 2011, 217, 1-44.	0.8	180
53	Inherited Apolipoprotein A-V Deficiency in Severe Hypertriglyceridemia. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2005, 25, 411-417.	2.4	177
54	Plasma resistin levels correlate with determinants of the metabolic syndrome. <i>European Journal of Endocrinology</i> , 2007, 156, 279-284.	3.7	176

#	ARTICLE	IF	CITATIONS
55	2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia. <i>European Heart Journal</i> , 2018, 39, 1131-1143.	2.2	171
56	Reducing the Clinical and Public Health Burden of Familial Hypercholesterolemia. <i>JAMA Cardiology</i> , 2020, 5, 217.	6.1	169
57	Mipomersen, an Antisense Oligonucleotide to Apolipoprotein B-100, Reduces Lipoprotein(a) in Various Populations With Hypercholesterolemia. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2015, 35, 689-699.	2.4	165
58	Leptin:Adiponectin Ratio Is an Independent Predictor of Intima Media Thickness of the Common Carotid Artery. <i>Stroke</i> , 2007, 38, 2844-2846.	2.0	164
59	Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). <i>Atherosclerosis</i> , 2018, 277, 234-255.	0.8	163
60	Optimizing Cholesterol Treatment in Patients With Muscle Complaints. <i>Journal of the American College of Cardiology</i> , 2017, 70, 1290-1301.	2.8	162
61	Emerging role of high density lipoproteins as a player in the immune system. <i>Atherosclerosis</i> , 2012, 220, 11-21.	0.8	158
62	Familial hypercholesterolaemia: A global call to arms. <i>Atherosclerosis</i> , 2015, 243, 257-259.	0.8	148
63	Update on cardiovascular prevention in clinical practice: A position paper of the European Association of Preventive Cardiology of the European Society of Cardiology. <i>European Journal of Preventive Cardiology</i> , 2020, 27, 181-205.	1.8	148
64	Meta-analysis of the cholesterol-lowering effect of ezetimibe added to ongoing statin therapy. <i>Current Medical Research and Opinion</i> , 2007, 23, 2009-2026.	1.9	146
65	HDL in Infectious Diseases and Sepsis. <i>Handbook of Experimental Pharmacology</i> , 2015, 224, 483-508.	1.8	145
66	Apolipoprotein C-III: From Pathophysiology to Pharmacology. <i>Trends in Pharmacological Sciences</i> , 2015, 36, 675-687.	8.7	144
67	Low-Density Lipoprotein Cholesterol Lowering for the Primary Prevention of Cardiovascular Disease Among Men With Primary Elevations of Low-Density Lipoprotein Cholesterol Levels of 190 mg/dL or Above. <i>Circulation</i> , 2017, 136, 1878-1891.	1.6	144
68	Association of Genetic Variants Related to Combined Exposure to Lower Low-Density Lipoproteins and Lower Systolic Blood Pressure With Lifetime Risk of Cardiovascular Disease. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 1381.	7.4	144
69	Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). <i>Lancet, The</i> , 2021, 398, 1713-1725.	13.7	142
70	Dihydrotestosterone Decreases Tumor Necrosis Factor- α and Lipopolysaccharide-Induced Inflammatory Response in Human Endothelial Cells. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006, 91, 546-554.	3.6	139
71	Long Pentraxin 3, a Key Component of Innate Immunity, Is Modulated by High-Density Lipoproteins in Endothelial Cells. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2008, 28, 925-931.	2.4	137
72	European Society of Cardiology/European Atherosclerosis Society Task Force consensus statement on proprotein convertase subtilisin/kexin type 9 inhibitors: practical guidance for use in patients at very high cardiovascular risk. <i>European Heart Journal</i> , 2017, 38, ehw480.	2.2	137

#	ARTICLE	IF	CITATIONS
73	Quantifying atherogenic lipoproteins for lipid-lowering strategies: Consensus-based recommendations from EAS and EFLM. <i>Atherosclerosis</i> , 2020, 294, 46-61.	0.8	137
74	The Long Pentraxin PTX3: A Modulator of the Immunoinflammatory Response in Atherosclerosis and Cardiovascular Diseases. <i>Trends in Cardiovascular Medicine</i> , 2010, 20, 35-40.	4.9	136
75	Anti-inflammatory and anti-atherogenic effects of catechin, caffeic acid and trans-resveratrol in apolipoprotein E deficient mice. <i>Atherosclerosis</i> , 2007, 191, 265-271.	0.8	131
76	Long-term effect of high dose omega-3 fatty acid supplementation for secondary prevention of cardiovascular outcomes: A meta-analysis of randomized, double blind, placebo controlled trials. <i>Atherosclerosis Supplements</i> , 2013, 14, 243-251.	1.2	131
77	An acidic microenvironment sets the humoral pattern recognition molecule PTX3 in a tissue repair mode. <i>Journal of Experimental Medicine</i> , 2015, 212, 905-925.	8.5	128
78	Familial hypercholesterolemia treatments: Guidelines and new therapies. <i>Atherosclerosis</i> , 2018, 277, 483-492.	0.8	128
79	Association of Bempedoic Acid Administration With Atherogenic Lipid Levels in Phase 3 Randomized Clinical Trials of Patients With Hypercholesterolemia. <i>JAMA Cardiology</i> , 2020, 5, 1124.	6.1	128
80	Circulating CD4 ⁺ CD25 ^{hi} CD127 ^{lo} Regulatory T-Cell Levels Do Not Reflect the Extent or Severity of Carotid and Coronary Atherosclerosis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2010, 30, 1832-1841.	2.4	125
81	Obesity-Induced Metabolic Stress Leads to Biased Effector Memory CD4 ⁺ T Cell Differentiation via PI3K p110 β -Akt-Mediated Signals. <i>Cell Metabolism</i> , 2017, 25, 593-609.	16.2	124
82	PCSK9 deficiency reduces insulin secretion and promotes glucose intolerance: the role of the low-density lipoprotein receptor. <i>European Heart Journal</i> , 2019, 40, 357-368.	2.2	124
83	Post-prandial endothelial dysfunction in hypertriglyceridemic subjects: Molecular mechanisms and gene expression studies. <i>Atherosclerosis</i> , 2007, 193, 321-327.	0.8	122
84	Moderate alcohol use and health: A consensus document. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2013, 23, 487-504.	2.6	120
85	The safety of therapeutic monoclonal antibodies: Implications for cardiovascular disease and targeting the PCSK9 pathway. <i>Atherosclerosis</i> , 2013, 228, 18-28.	0.8	119
86	Quantifying atherogenic lipoproteins for lipid-lowering strategies: consensus-based recommendations from EAS and EFLM. <i>Clinical Chemistry and Laboratory Medicine</i> , 2020, 58, 496-517.	2.3	119
87	Effector Memory T cells Are Associated With Atherosclerosis in Humans and Animal Models. <i>Journal of the American Heart Association</i> , 2012, 1, 27-41.	3.7	114
88	Rare dyslipidaemias, from phenotype to genotype to management: a European Atherosclerosis Society task force consensus statement. <i>Lancet Diabetes and Endocrinology</i> , 2020, 8, 50-67.	11.4	114
89	Reduction of low density lipoprotein-cholesterol and cardiovascular events with proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors and statins: an analysis of FOURIER, SPIRE, and the Cholesterol Treatment Trialists Collaboration. <i>European Heart Journal</i> , 2018, 39, 2540-2545.	2.2	113
90	Statin use and risk of new-onset diabetes: A meta-analysis of observational studies. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2017, 27, 396-406.	2.6	111

#	ARTICLE	IF	CITATIONS
91	Biology of proprotein convertase subtilisin kexin 9: beyond low-density lipoprotein cholesterol lowering. <i>Cardiovascular Research</i> , 2016, 112, 429-442.	3.8	105
92	Vascular inflammation and low-density lipoproteins: is cholesterol the link? A lesson from the clinical trials. <i>British Journal of Pharmacology</i> , 2017, 174, 3973-3985.	5.4	105
93	Lipid-altering efficacy of the ezetimibe/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients. <i>Current Medical Research and Opinion</i> , 2006, 22, 2041-2053.	1.9	101
94	Side Effects of Anabolic Androgenic Steroids Abuse. <i>International Journal of Sports Medicine</i> , 2008, 29, 679-687.	1.7	96
95	Targeting PCSK9 for Hypercholesterolemia. <i>Annual Review of Pharmacology and Toxicology</i> , 2014, 54, 273-293.	9.4	96
96	Effect of a standardized grape seed extract on low-density lipoprotein susceptibility to oxidation in heavy smokers. <i>Metabolism: Clinical and Experimental</i> , 2003, 52, 1250-1257.	3.4	95
97	Severe hypercholesterolaemia: therapeutic goals and eligibility criteria for LDL apheresis in Europe. <i>Current Opinion in Lipidology</i> , 2010, 21, 492-498.	2.7	95
98	Proprotein convertase subtilisin/kexin type 9 (PCSK9): From structure to function relation to therapeutic inhibition. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2011, 21, 835-843.	2.6	95
99	Myeloid apolipoprotein E controls dendritic cell antigen presentation and T cell activation. <i>Nature Communications</i> , 2018, 9, 3083.	12.8	95
100	Circulating soluble receptor for advanced glycation end products is inversely associated with body mass index and waist/hip ratio in the general population. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2009, 19, 129-134.	2.6	94
101	Postprandial lipemia as a cardiometabolic risk factor. <i>Current Medical Research and Opinion</i> , 2014, 30, 1489-1503.	1.9	94
102	HDL Induces Cyclooxygenase-2 Expression and Prostacyclin Release in Human Endothelial Cells Via a p38 MAPK/CRE-Dependent Pathway: Effects on COX-2/PGI-Synthase Coupling. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2004, 24, 871-877.	2.4	92
103	The new joint EAS/ESC guidelines for the management of dyslipidaemias. <i>Atherosclerosis</i> , 2011, 217, 1.	0.8	92
104	The Arachidonic Acid Metabolome Serves as a Conserved Regulator of Cholesterol Metabolism. <i>Cell Metabolism</i> , 2014, 20, 787-798.	16.2	92
105	Oral L-arginine supplementation improves endothelial function and ameliorates insulin sensitivity and inflammation in cardiopathic nondiabetic patients after an aortocoronary bypass. <i>Metabolism: Clinical and Experimental</i> , 2009, 58, 1270-1276.	3.4	91
106	New therapeutic principles in dyslipidaemia: focus on LDL and Lp(a) lowering drugs. <i>European Heart Journal</i> , 2013, 34, 1783-1789.	2.2	90
107	Pooling and expanding registries of familial hypercholesterolaemia to assess gaps in care and improve disease management and outcomes: Rationale and design of the global EAS Familial Hypercholesterolaemia Studies Collaboration. <i>Atherosclerosis Supplements</i> , 2016, 22, 1-32.	1.2	90
108	Long Pentraxin 3: Experimental and Clinical Relevance in Cardiovascular Diseases. <i>Mediators of Inflammation</i> , 2013, 2013, 1-10.	3.0	89

#	ARTICLE	IF	CITATIONS
109	MiR-143/145 deficiency attenuates the progression of atherosclerosis in Ldlr ^{-/-} mice. <i>Thrombosis and Haemostasis</i> , 2014, 112, 796-802.	3.4	87
110	Cardiovascular risk assessment beyond Systemic Coronary Risk Estimation. <i>Journal of Hypertension</i> , 2012, 30, 1056-1064.	0.5	86
111	Unique Epitope of Apolipoprotein A-I Expressed in Pre-beta ₁ High-Density Lipoprotein and Its Role in the Catalyzed Efflux of Cellular Cholesterol. <i>Biochemistry</i> , 1994, 33, 6981-6985.	2.5	85
112	High-Density Lipoproteins Induce Transforming Growth Factor- β 2 Expression in Endothelial Cells. <i>Circulation</i> , 2005, 111, 2805-2811.	1.6	84
113	Statins and the Risk of Diabetes: Evidence From a Large Population-Based Cohort Study. <i>Diabetes Care</i> , 2014, 37, 2225-2232.	8.6	83
114	Practical guidance for combination lipid-modifying therapy in high- and very-high-risk patients: A statement from a European Atherosclerosis Society Task Force. <i>Atherosclerosis</i> , 2021, 325, 99-109.	0.8	83
115	Low density lipoprotein oxidation, antioxidants, and atherosclerosis. <i>Current Opinion in Cardiology</i> , 2000, 15, 355-363.	1.8	82
116	Effects of an Automated Electronic Reminder in Changing the Antiplatelet Drug-Prescribing Behavior Among Italian General Practitioners in Diabetic Patients: An intervention trial. <i>Diabetes Care</i> , 2003, 26, 1497-1500.	8.6	82
117	Antioxidant Effect of Flavonoids. <i>Angiology</i> , 1997, 48, 39-44.	1.8	80
118	Barriers to cardiovascular disease risk scoring and primary prevention in Europe. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2010, 103, 727-739.	0.5	80
119	Genetic and phenotypic heterogeneity in familial lecithin: cholesterol acyltransferase (LCAT) deficiency. Six newly identified defective alleles further contribute to the structural heterogeneity in this disease. <i>Journal of Clinical Investigation</i> , 1993, 91, 677-683.	8.2	80
120	High density lipoprotein cholesterol and cancer: Marker or causative?. <i>Progress in Lipid Research</i> , 2018, 71, 54-69.	11.6	79
121	PCSK9 knock-out mice are protected from neointimal formation in response to perivascular carotid collar placement. <i>Atherosclerosis</i> , 2016, 253, 214-224.	0.8	78
122	Progression of carotid vascular damage and cardiovascular events in non-alcoholic fatty liver disease patients compared to the general population during 10 years of follow-up. <i>Atherosclerosis</i> , 2016, 246, 208-213.	0.8	78
123	Results of a retrospective database analysis of adherence to statin therapy and risk of nonfatal ischemic heart disease in daily clinical practice in Italy. <i>Clinical Therapeutics</i> , 2010, 32, 300-310.	2.5	76
124	Cholesterol metabolism, pancreatic β -cell function and diabetes. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2019, 1865, 2149-2156.	3.8	76
125	Modified HDL: Biological and physiopathological consequences. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2006, 16, 371-386.	2.6	75
126	Effect of the Toll-like receptor 4 (TLR-4) variants on intima-media thickness and monocyte-derived macrophage response to LPS. <i>Journal of Internal Medicine</i> , 2005, 258, 21-27.	6.0	74

#	ARTICLE	IF	CITATIONS
127	Effects of PCSK9 variants on common carotid artery intima media thickness and relation to ApoE alleles. <i>Atherosclerosis</i> , 2010, 208, 177-182.	0.8	74
128	Inflammatory markers and extent and progression of early atherosclerosis: Meta-analysis of individual-participant-data from 20 prospective studies of the PROG-IMT collaboration. <i>European Journal of Preventive Cardiology</i> , 2016, 23, 194-205.	1.8	74
129	Antidrug Antibodies in Patients Treated with Alirocumab. <i>New England Journal of Medicine</i> , 2017, 376, 1589-1590.	27.0	73
130	Lipids and Lipoproteins in 2020. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 595.	7.4	73
131	Lipolysis of ApoC-II deficient very low density lipoproteins: Enhancement of lipoprotein lipase action by synthetic fragments of ApoC-II. <i>Biochemical and Biophysical Research Communications</i> , 1979, 89, 951-957.	2.1	71
132	Current practice in identifying and treating cardiovascular risk, with a focus on residual risk associated with atherogenic dyslipidaemia. <i>European Heart Journal Supplements</i> , 2016, 18, C2-C12.	0.1	71
133	Role of Bempedoic Acid in Clinical Practice. <i>Cardiovascular Drugs and Therapy</i> , 2021, 35, 853-864.	2.6	71
134	Experimental hypothyroidism modulates the expression of the low density lipoprotein receptor by the liver. <i>Atherosclerosis</i> , 1986, 59, 329-333.	0.8	70
135	Statins and primary liver cancer. <i>European Journal of Cancer Prevention</i> , 2013, 22, 229-234.	1.3	70
136	Bempedoic acid safety analysis: Pooled data from four phase 3 clinical trials. <i>Journal of Clinical Lipidology</i> , 2020, 14, 649-659.e6.	1.5	70
137	Lipoprotein Remnants and Endothelial Dysfunction in the Postprandial Phase. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 2946-2950.	3.6	69
138	Small dense LDL and VLDL predict common carotid artery IMT and elicit an inflammatory response in peripheral blood mononuclear and endothelial cells. <i>Atherosclerosis</i> , 2009, 206, 556-562.	0.8	69
139	Associations between very low concentrations of low density lipoprotein cholesterol, high sensitivity C-reactive protein, and health outcomes in the Reasons for Geographical and Racial Differences in Stroke (REGARDS) study. <i>European Heart Journal</i> , 2018, 39, 3641-3653.	2.2	69
140	Worldwide experience of homozygous familial hypercholesterolaemia: retrospective cohort study. <i>Lancet</i> , The, 2022, 399, 719-728.	13.7	69
141	High density lipoprotein cholesterol levels are an independent predictor of the progression of chronic kidney disease. <i>Journal of Internal Medicine</i> , 2013, 274, 252-262.	6.0	68
142	Improved cardiovascular risk prediction using targeted plasma proteomics in primary prevention. <i>European Heart Journal</i> , 2020, 41, 3998-4007.	2.2	68
143	Acute Effect of High-Fat Meal on Endothelial Function in Moderately Dyslipidemic Subjects. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2005, 25, 406-410.	2.4	67
144	Carotid Intima-Media Thickness Progression and Risk of Vascular Events in People With Diabetes: Results From the PROG-IMT Collaboration. <i>Diabetes Care</i> , 2015, 38, 1921-1929.	8.6	67

#	ARTICLE	IF	CITATIONS
145	The Interplay of Lipids, Lipoproteins, and Immunity in Atherosclerosis. <i>Current Atherosclerosis Reports</i> , 2018, 20, 12.	4.8	67
146	A review of the evidence on reducing macrovascular risk in patients with atherogenic dyslipidaemia: A report from an expert consensus meeting on the role of fenofibrate+statin combination therapy. <i>Atherosclerosis Supplements</i> , 2015, 19, 1-12.	1.2	66
147	In vivo assimilation of low density lipoproteins by a fibrosarcoma tumour line in mice. <i>Cancer Letters</i> , 1984, 25, 203-208.	7.2	65
148	Spectrum of mutations in Italian patients with familial hypercholesterolemia: New results from the LIPIGEN study. <i>Atherosclerosis Supplements</i> , 2017, 29, 17-24.	1.2	65
149	Biological Consequences of Dysfunctional HDL. <i>Current Medicinal Chemistry</i> , 2019, 26, 1644-1664.	2.4	65
150	Statin-associated myopathy and the quest for biomarkers: can we effectively predict statin-associated muscle symptoms?. <i>Drug Discovery Today</i> , 2017, 22, 85-96.	6.4	64
151	Novel strategies to target proprotein convertase subtilisin kexin 9: beyond monoclonal antibodies. <i>Cardiovascular Research</i> , 2019, 115, 510-518.	3.8	63
152	Molecular mechanisms responsible for the antiinflammatory and protective effect of HDL on the endothelium. <i>Vascular Health and Risk Management</i> , 2005, 1, 119-129.	2.3	63
153	miR-30c-5p regulates macrophage-mediated inflammation and pro-atherosclerosis pathways. <i>Cardiovascular Research</i> , 2017, 113, 1627-1638.	3.8	62
154	Effect of the -420C/G variant of the resistin gene promoter on metabolic syndrome, obesity, myocardial infarction and kidney dysfunction. <i>Journal of Internal Medicine</i> , 2007, 262, 104-112.	6.0	60
155	Soluble Lectin-Like Oxidized Low Density Lipoprotein Receptor-1 as a Biochemical Marker for Atherosclerosis-Related Diseases. <i>Disease Markers</i> , 2013, 35, 413-418.	1.3	60
156	Oxidized-LDL Induce the Expression of Heat Shock Protein 70 in Human Endothelial Cells. <i>Biochemical and Biophysical Research Communications</i> , 1994, 200, 389-394.	2.1	59
157	Gene expression and intracellular pathways involved in endothelial dysfunction induced by VLDL and oxidised VLDL. <i>Cardiovascular Research</i> , 2003, 59, 169-180.	3.8	59
158	Effect of a long-term oral L-arginine supplementation on glucose metabolism: a randomized, double-blind, placebo-controlled trial. <i>Diabetes, Obesity and Metabolism</i> , 2012, 14, 893-900.	4.4	58
159	Abdominal visceral fat measurement using dual-energy X-ray: Association with cardiometabolic risk factors. <i>Obesity</i> , 2013, 21, 1798-1802.	3.0	58
160	Very low density lipoproteins in normal and cholesterol-fed rabbits: lipid and protein composition and metabolism. <i>Atherosclerosis</i> , 1976, 23, 85-96.	0.8	57
161	Identification and management of patients with statin-associated symptoms in clinical practice: A clinician survey. <i>Atherosclerosis</i> , 2016, 245, 111-117.	0.8	57
162	Triglyceride-rich lipoproteins from hypertriglyceridemic subjects induce a pro-inflammatory response in the endothelium: Molecular mechanisms and gene expression studies. <i>Journal of Molecular and Cellular Cardiology</i> , 2006, 40, 484-494.	1.9	55

#	ARTICLE	IF	CITATIONS
163	PCSK9 deficiency results in increased ectopic fat accumulation in experimental models and in humans. <i>European Journal of Preventive Cardiology</i> , 2017, 24, 1870-1877.	1.8	55
164	Targeted proteomics improves cardiovascular risk prediction in secondary prevention. <i>European Heart Journal</i> , 2022, 43, 1569-1577.	2.2	55
165	Lecithin cholesterol acyl transferase deficiency: molecular analysis of a mutated allele. <i>Human Genetics</i> , 1990, 85, 195-9.	3.8	54
166	Defective catabolism of oxidized LDL by J774 murine macrophages.. <i>Journal of Lipid Research</i> , 1992, 33, 819-829.	4.2	54
167	ACTIVATION OF LIPOPROTEIN LIPASE BY SYNTHETIC FRAGMENTS OF APOLIPOPROTEIN C-II. <i>Annals of the New York Academy of Sciences</i> , 1980, 348, 213-223.	3.8	53
168	Oxidised-HDL3 induces the expression of PAI-1 in human endothelial cells. Role of p38MAPK activation and mRNA stabilization. <i>British Journal of Haematology</i> , 2004, 127, 97-104.	2.5	53
169	Familial hypercholesterolemia: The Italian Atherosclerosis Society Network (LIPIGEN). <i>Atherosclerosis Supplements</i> , 2017, 29, 11-16.	1.2	53
170	Non-pharmacological control of plasma cholesterol levels. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2008, 18, S1-S16.	2.6	52
171	Translating the biology of adipokines in atherosclerosis and cardiovascular diseases: Gaps and open questions. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2017, 27, 379-395.	2.6	52
172	Predictive value for cardiovascular events of common carotid intima media thickness and its rate of change in individuals at high cardiovascular risk – Results from the PROG-IMT collaboration. <i>PLoS ONE</i> , 2018, 13, e0191172.	2.5	51
173	Evidence for the presence of 7-hydroperoxycholest-5-en-3 β -ol in oxidized human LDL. <i>Chemistry and Physics of Lipids</i> , 1992, 62, 209-214.	3.2	50
174	Ezetimibe: a selective inhibitor of cholesterol absorption. <i>European Heart Journal Supplements</i> , 2001, 3, E6-E10.	0.1	50
175	Single systemic transfer of a human gene associated with exceptional longevity halts the progression of atherosclerosis and inflammation in ApoE knockout mice through a CXCR4-mediated mechanism. <i>European Heart Journal</i> , 2020, 41, 2487-2497.	2.2	50
176	PCSK9 deficiency rewires heart metabolism and drives heart failure with preserved ejection fraction. <i>European Heart Journal</i> , 2021, 42, 3078-3090.	2.2	50
177	Telomere shortening over 6 \hat{A} years is associated with increased subclinical carotid vascular damage and worse cardiovascular prognosis in the general population. <i>Journal of Internal Medicine</i> , 2015, 277, 478-487.	6.0	49
178	Effects of Fractalkine Receptor Variants on Common Carotid Artery Intima-Media Thickness. <i>Stroke</i> , 2006, 37, 1558-1561.	2.0	48
179	Increased atherosclerosis and vascular inflammation in APP transgenic mice with apolipoprotein E deficiency. <i>Atherosclerosis</i> , 2010, 210, 78-87.	0.8	48
180	Statins and skeletal muscles toxicity: From clinical trials to everyday practice. <i>Pharmacological Research</i> , 2014, 88, 107-113.	7.1	48

#	ARTICLE	IF	CITATIONS
181	Evaluation of the performance of Dutch Lipid Clinic Network score in an Italian FH population: The LIPIGEN study. <i>Atherosclerosis</i> , 2018, 277, 413-418.	0.8	48
182	Oxidized LDL increase free cholesterol and fail to stimulate cholesterol esterification in murine macrophages. <i>Biochemical and Biophysical Research Communications</i> , 1990, 171, 123-131.	2.1	47
183	HDL in Atherosclerotic Cardiovascular Disease: In Search of a Role. <i>Cells</i> , 2021, 10, 1869.	4.1	46
184	Statin use and risk of dementia or Alzheimer's disease: a systematic review and meta-analysis of observational studies. <i>European Journal of Preventive Cardiology</i> , 2022, 29, 804-814.	1.8	46
185	The distribution of apo C-II and apo C-III in very low density lipoproteins of normal and type iv subjects. <i>Atherosclerosis</i> , 1980, 35, 419-424.	0.8	45
186	Effects of calcium antagonists on lipids and atherosclerosis. <i>American Journal of Cardiology</i> , 1989, 64, 1129-1134.	1.6	45
187	Translating the microRNA signature of microvesicles derived from human coronary artery smooth muscle cells in patients with familial hypercholesterolemia and coronary artery disease. <i>Journal of Molecular and Cellular Cardiology</i> , 2017, 106, 55-67.	1.9	45
188	Efficacy and Safety of Alternate-Day Versus Daily Dosing of Statins: a Systematic Review and Meta-Analysis. <i>Cardiovascular Drugs and Therapy</i> , 2017, 31, 419-431.	2.6	45
189	Statin-Induced Myotoxicity: Pharmacokinetic Differences among Statins and the Risk of Rhabdomyolysis, with Particular Reference to Pitavastatin. <i>Current Vascular Pharmacology</i> , 2012, 10, 257-267.	1.7	44
190	Monocyte and haematopoietic progenitor reprogramming as common mechanism underlying chronic inflammatory and cardiovascular diseases. <i>European Heart Journal</i> , 2018, 39, 3521-3527.	2.2	44
191	The Expected 30-Year Benefits of Early Versus Delayed Primary Prevention of Cardiovascular Disease by Lipid Lowering. <i>Circulation</i> , 2020, 142, 827-837.	1.6	44
192	Adherence to lipid-lowering treatment: the patient perspective. <i>Patient Preference and Adherence</i> , 2012, 6, 805.	1.8	43
193	Identification of AnnexinA1 as an Endogenous Regulator of RhoA, and Its Role in the Pathophysiology and Experimental Therapy of Type-2 Diabetes. <i>Frontiers in Immunology</i> , 2019, 10, 571.	4.8	43
194	Abnormal suppression of 3-hydroxy-3-methylglutaryl-CoA reductase activity in cultured human fibroblasts by hypertriglyceridemic very low density lipoprotein subclasses. <i>Lipids</i> , 1980, 15, 456-463.	1.7	42
195	Protection of low-density lipoprotein from oxidation by 3,4-dihydroxyphenylethanol. <i>Lancet</i> , The, 1994, 343, 1296-1297.	13.7	42
196	Lipid altering-efficacy of ezetimibe co-administered with simvastatin compared with rosuvastatin: a meta-analysis of pooled data from 14 clinical trials. <i>Current Medical Research and Opinion</i> , 2005, 21, 1123-1130.	1.9	42
197	Subclinical atherosclerosis is associated with Epicardial Fat Thickness and hepatic steatosis in the general population. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2016, 26, 141-153.	2.6	42
198	HDLs, immunity, and atherosclerosis. <i>Current Opinion in Lipidology</i> , 2011, 22, 410-416.	2.7	41

#	ARTICLE	IF	CITATIONS
199	Epicardial Adipose Tissue (EAT) Thickness Is Associated with Cardiovascular and Liver Damage in Nonalcoholic Fatty Liver Disease. <i>PLoS ONE</i> , 2016, 11, e0162473.	2.5	41
200	New Pharmacological Approaches to Target PCSK9. <i>Current Atherosclerosis Reports</i> , 2020, 22, 24.	4.8	41
201	Suppression of 3-hydroxy-3-methylglutaryl-CoA reductase by low density lipoproteins produced in vitro by lipoprotein lipase action on nonsuppressive very low density lipoproteins.. <i>Journal of Biological Chemistry</i> , 1979, 254, 1007-1009.	3.4	41
202	Prevalence of the Prescription of Potentially Interacting Drugs. <i>PLoS ONE</i> , 2013, 8, e78827.	2.5	41
203	Assimilation of LDL by experimental tumours in mice. <i>Lipids and Lipid Metabolism</i> , 1989, 1003, 301-306.	2.6	40
204	Role of Vitamin E-Coated Membrane in Reducing Advanced Glycation End Products in Hemodialysis Patients: A Pilot Study. <i>Blood Purification</i> , 2006, 24, 369-376.	1.8	40
205	Safety and efficacy of mipomersen in patients with heterozygous familial hypercholesterolemia. <i>Atherosclerosis</i> , 2019, 280, 109-117.	0.8	40
206	Perspectives on low-density lipoprotein cholesterol goal achievement. <i>Current Medical Research and Opinion</i> , 2009, 25, 431-447.	1.9	39
207	Combination therapy in dyslipidemia: Where are we now?. <i>Atherosclerosis</i> , 2014, 237, 319-335.	0.8	39
208	Cardiometabolic and immune factors associated with increased common carotid artery intima-media thickness and cardiovascular disease in patients with systemic lupus erythematosus. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2014, 24, 751-759.	2.6	39
209	Plasma lipids, lipoproteins and apoproteins in a case of apo C-II deficiency. <i>Clinica Chimica Acta</i> , 1983, 130, 317-327.	1.1	38
210	Bempedoic acid in patients with type 2 diabetes mellitus, prediabetes, and normoglycaemia: A post hoc analysis of efficacy and glycaemic control using pooled data from phase 3 clinical trials. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 868-880.	4.4	38
211	Metformin: An antiatherosclerotic agent modifying very low density lipoproteins in rabbits. <i>Atherosclerosis</i> , 1977, 26, 79-89.	0.8	37
212	Stress proteins and atherosclerosis. <i>Atherosclerosis</i> , 1996, 127, 147-154.	0.8	37
213	Individual progression of carotid intima media thickness as a surrogate for vascular risk (PROG-IMT): Rationale and design of a meta-analysis project. <i>American Heart Journal</i> , 2010, 159, 730-736.e2.	2.7	37
214	Pitavastatin " pharmacological profile from early phase studies. <i>Atherosclerosis Supplements</i> , 2010, 11, 3-7.	1.2	37
215	The androgen derivative 5 α -androstane-3 β ,17 β -diol inhibits tumor necrosis factor α and lipopolysaccharide induced inflammatory response in human endothelial cells and in mice aorta. <i>Atherosclerosis</i> , 2010, 212, 100-106.	0.8	37
216	Are generic and brand-name statins clinically equivalent? Evidence from a real data-base. <i>European Journal of Internal Medicine</i> , 2014, 25, 745-750.	2.2	37

#	ARTICLE	IF	CITATIONS
217	Upregulation of lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) by 15-lipoxygenase-modified LDL in endothelial cells. <i>Atherosclerosis</i> , 2011, 214, 331-337.	0.8	36
218	MicroRNAs and lipoproteins: A connection beyond atherosclerosis?. <i>Atherosclerosis</i> , 2013, 227, 209-215.	0.8	36
219	Pentraxin 3 deficiency protects from the metabolic inflammation associated to diet-induced obesity. <i>Cardiovascular Research</i> , 2019, 115, 1861-1872.	3.8	36
220	P2X7 Receptor Activity Limits Accumulation of T Cells within Tumors. <i>Cancer Research</i> , 2020, 80, 3906-3919.	0.9	36
221	Long-term use of statins reduces the risk of hospitalization for dementia. <i>Atherosclerosis</i> , 2013, 230, 171-176.	0.8	35
222	Oxidized LDL induce hsp70 expression in human smooth muscle cells. <i>FEBS Letters</i> , 1995, 372, 1-5.	2.8	34
223	15-Lipoxygenase-mediated modification of high-density lipoproteins impairs SR-BI- and ABCA1-dependent cholesterol efflux from macrophages. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2006, 1761, 292-300.	2.4	34
224	Understanding IMPROVE-IT and the cardinal role of LDL-C lowering in CVD prevention. <i>European Heart Journal</i> , 2014, 35, 1996-2000.	2.2	34
225	Prevalence and management of familial hypercholesterolemia in patients with coronary artery disease: The heredity survey. <i>International Journal of Cardiology</i> , 2018, 252, 193-198.	1.7	34
226	Update on the efficacy and safety of combination ezetimibe plus statin therapy. <i>Clinical Lipidology</i> , 2010, 5, 655-684.	0.4	33
227	Normative values for carotid intima media thickness and its progression: Are they transferrable outside of their cohort of origin?. <i>European Journal of Preventive Cardiology</i> , 2016, 23, 1165-1173.	1.8	33
228	Impact of protein glycosylation on lipoprotein metabolism and atherosclerosis. <i>Cardiovascular Research</i> , 2021, 117, 1033-1045.	3.8	33
229	Apolipoprotein C-II deficiency presenting as a lipid encephalopathy in infancy. <i>Annals of Neurology</i> , 2003, 53, 807-810.	5.3	32
230	High-density lipoprotein subfraction 3 decreases ADAMTS-1 expression induced by lipopolysaccharide and tumor necrosis factor- α in human endothelial cells. <i>Matrix Biology</i> , 2004, 22, 557-560.	3.6	32
231	Omega-3 polyunsaturated fatty acids in the treatment of hypertriglyceridaemia. <i>International Journal of Cardiology</i> , 2013, 170, S16-S20.	1.7	32
232	Statin Intolerance: Diagnosis and Remedies. <i>Current Cardiology Reports</i> , 2015, 17, 27.	2.9	32
233	Vascular pentraxin 3 controls arterial thrombosis by targeting collagen and fibrinogen induced platelets aggregation. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2016, 1862, 1182-1190.	3.8	32
234	Circulating CD14 ⁺ and CD14 ^{high} CD16 ⁺ classical monocytes are reduced in patients with signs of plaque neovascularization in the carotid artery. <i>Atherosclerosis</i> , 2016, 255, 171-178.	0.8	32

#	ARTICLE	IF	CITATIONS
235	Comparison of PCSK9 Inhibitor Evolocumab vs Ezetimibe in Statin-Intolerant Patients: Design of the Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin-Intolerant Subjects 3 (GAUSS-3) Trial. <i>Clinical Cardiology</i> , 2016, 39, 137-144.	1.8	32
236	Long-Term Safety and Efficacy of Bempedoic Acid in Patients With Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia (from the CLEAR Harmony Open-Label) <i>Tj ETQq0 0 0 rgBT /Overlook 10 Tf 5</i>	3.8	31
237	Effect of lercanidipine and its (R)-enantiomer on atherosclerotic lesions induced in hypercholesterolemic rabbits. <i>British Journal of Pharmacology</i> , 1998, 125, 1471-1476.	5.4	31
238	Novel concepts in HDL pharmacology. <i>Cardiovascular Research</i> , 2014, 103, 423-428.	3.8	31
239	Pentraxin 3 (PTX3) plasma levels and carotid intima media thickness progression in the general population. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2014, 24, 518-523.	2.6	31
240	Statin utilization and lipid goal attainment in high or very-high cardiovascular risk patients: Insights from Italian general practice. <i>Atherosclerosis</i> , 2018, 271, 120-127.	0.8	31
241	Disease trends over time and CD4 + CCR5 + T-cells expansion predict carotid atherosclerosis development in patients with systemic lupus erythematosus. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2018, 28, 53-63.	2.6	31
242	The role of red yeast rice (RYR) supplementation in plasma cholesterol control: A review and expert opinion. <i>Atherosclerosis Supplements</i> , 2019, 39, e1-e8.	1.2	31
243	Adoptive transfer of CX3CR1 transduced-T regulatory cells improves homing to the atherosclerotic plaques and dampens atherosclerosis progression. <i>Cardiovascular Research</i> , 2021, 117, 2069-2082.	3.8	31
244	Simvastatin Modulates the Heat Shock Response and Cytotoxicity Mediated by Oxidized LDL in Cultured Human Endothelial Smooth Muscle Cells. <i>Biochemical and Biophysical Research Communications</i> , 1997, 231, 437-441.	2.1	30
245	Novel statins: pharmacological and clinical results. <i>Cardiovascular Drugs and Therapy</i> , 2002, 16, 251-257.	2.6	30
246	Lower incidence of macrovascular complications in patients on insulin glargine versus those on basal human insulins: A population-based cohort study in Italy. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2014, 24, 10-17.	2.6	30
247	PCSK9 inhibition for the treatment of hypercholesterolemia: Promises and emerging challenges. <i>Vascular Pharmacology</i> , 2014, 62, 103-111.	2.1	30
248	Medication persistence and the use of generic and brand-name blood pressure-lowering agents. <i>Journal of Hypertension</i> , 2014, 32, 1146-1153.	0.5	30
249	World Heart Federation Cholesterol Roadmap. <i>Global Heart</i> , 2017, 12, 179.	2.3	30
250	Omega-3 polyunsaturated fatty acids supplementation and cardiovascular outcomes: do formulation, dosage, and baseline cardiovascular risk matter? An updated meta-analysis of randomized controlled trials. <i>Pharmacological Research</i> , 2020, 160, 105060.	7.1	30
251	Autoantibodies to the low density lipoprotein receptor in a subject affected by severe hypercholesterolemia.. <i>Journal of Clinical Investigation</i> , 1986, 78, 940-946.	8.2	30
252	Ability of the LDL receptor from several animal species to recognize the human apo B binding domain: studies with LDL from familial defective apo B-100. <i>Atherosclerosis</i> , 1992, 93, 95-103.	0.8	29

#	ARTICLE	IF	CITATIONS
253	Plasma adiponectin levels in chronic kidney disease patients: Relation with molecular inflammatory profile and metabolic status. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2010, 20, 56-63.	2.6	29
254	Microrna 143â€“145 Deficiency Impairs Vascular Function. <i>International Journal of Immunopathology and Pharmacology</i> , 2012, 25, 467-474.	2.1	29
255	Gene silencing approaches for the management of dyslipidaemia. <i>Trends in Pharmacological Sciences</i> , 2013, 34, 198-205.	8.7	29
256	Human Endothelial Cells Exposed to Oxidized LDL Express hsp70 Only When Proliferating. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1996, 16, 1104-1111.	2.4	29
257	Niemann-Pick C1-Like 1 (NPC1L1) Inhibition and Cardiovascular Diseases. <i>Current Medicinal Chemistry</i> , 2016, 23, 983-999.	2.4	29
258	Statins use and the risk of all and subtype hematological malignancies: a metaâ€“analysis of observational studies. <i>Cancer Medicine</i> , 2015, 4, 770-780.	2.8	28
259	The Interconnection Between Immuno-Metabolism, Diabetes, and CKD. <i>Current Diabetes Reports</i> , 2019, 19, 21.	4.2	28
260	Bile lipid composition and haemostatic variables in a case of high density lipoprotein deficiency (Tangier disease). <i>European Journal of Clinical Investigation</i> , 1984, 14, 49-54.	3.4	27
261	β -adrenergic receptors in brain microvessels of diabetic rats. <i>Life Sciences</i> , 1984, 34, 1095-1100.	4.3	27
262	Omega-3 polyunsaturated fatty acids in the treatment of atherogenic dyslipidemia. <i>Atherosclerosis Supplements</i> , 2013, 14, 237-242.	1.2	27
263	A randomized study investigating the safety, tolerability, and pharmacokinetics of evinacumab, an ANGPTL3 inhibitor, in healthy Japanese and Caucasian subjects. <i>Atherosclerosis</i> , 2020, 314, 33-40.	0.8	27
264	Treating High Density Lipoprotein Cholesterol (HDL-C): Quantity Versus Quality. <i>Current Pharmaceutical Design</i> , 2013, 19, 3841-3857.	1.9	27
265	In vitro isolation of circulating endothelial progenitor cells is related to the high density lipoprotein plasma levels. <i>International Journal of Molecular Medicine</i> , 2006, 17, 203-8.	4.0	27
266	Delapril slows the progression of atherosclerosis and maintains endothelial function in cholesterol-fed rabbits. <i>Atherosclerosis</i> , 1998, 137, 71-76.	0.8	26
267	Cost-effectiveness of enhancing adherence to therapy with statins in the setting of primary cardiovascular prevention. Evidence from an empirical approach based on administrative databases. <i>Atherosclerosis</i> , 2011, 217, 479-485.	0.8	26
268	IMPROVE-IT and genetics reaffirm the causal role of LDL in Cardiovascular Disease. <i>Atherosclerosis</i> , 2015, 241, 498-501.	0.8	26
269	Prevalence of potential familial hypercholesterolemia (FH) in 54,811 statin-treated patients in clinical practice. <i>Atherosclerosis</i> , 2016, 252, 1-8.	0.8	26
270	Efficacy of Statin Therapy in Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis. <i>Scientific Reports</i> , 2016, 6, 30060.	3.3	25

#	ARTICLE	IF	CITATIONS
271	Cardiovascular events with PCSK9 inhibitors: an updated meta-analysis of randomised controlled trials. <i>Pharmacological Research</i> , 2019, 143, 143-150.	7.1	25
272	Homozygous familial hypercholesterolemia in Italy: Clinical and molecular features. <i>Atherosclerosis</i> , 2020, 312, 72-78.	0.8	25
273	Identification of domains in apoA-I susceptible to proteolysis by mast cell chymase: implications for HDL function. <i>Journal of Lipid Research</i> , 2000, 41, 975-984.	4.2	25
274	Proteomics-Enabled Deep Learning Machine Algorithms Can Enhance Prediction of Mortality. <i>Journal of the American College of Cardiology</i> , 2021, 78, 1621-1631.	2.8	25
275	The Antiatherosclerotic Effect of Anipamil in Cholesterol-Fed Rabbits. <i>Annals of the New York Academy of Sciences</i> , 1988, 522, 519-521.	3.8	24
276	The 15-Lipoxygenase-Modified High Density Lipoproteins 3 Fail to Inhibit the TNF- α -Induced Inflammatory Response in Human Endothelial Cells. <i>Journal of Immunology</i> , 2008, 181, 2821-2830.	0.8	24
277	Different patterns characterize Omega 6 and Omega 3 long chain polyunsaturated fatty acid levels in blood from Italian infants, children, adults and elderly. <i>Prostaglandins Leukotrienes and Essential Fatty Acids</i> , 2013, 89, 215-220.	2.2	24
278	Mode of action of fibrates. <i>Pharmacological Research</i> , 1992, 26, 331-340.	7.1	23
279	5-methyltetrahydrofolate restores endothelial function in uraemic patients on convective haemodialysis. <i>Nephrology Dialysis Transplantation</i> , 2002, 17, 857-864.	0.7	23
280	Upregulation of lectin-like oxidized low density lipoprotein receptor 1 (LOX-1) expression in human endothelial cells by modified high density lipoproteins. <i>Biochemical and Biophysical Research Communications</i> , 2012, 428, 230-233.	2.1	23
281	Effect of treatment with pravastatin or ezetimibe on endothelial function in patients with moderate hypercholesterolemia. <i>European Journal of Clinical Pharmacology</i> , 2013, 69, 341-346.	1.9	23
282	The efficacy and safety of ezetimibe coadministered with statin therapy in various patient groups. <i>Clinical Lipidology</i> , 2013, 8, 13-41.	0.4	23
283	Zc3h10 is a novel mitochondrial regulator. <i>EMBO Reports</i> , 2018, 19, .	4.5	23
284	Multilevel Models to Estimate Carotid Intima-Media Thickness Curves for Individual Cardiovascular Risk Evaluation. <i>Stroke</i> , 2019, 50, 1758-1765.	2.0	23
285	HDL in Immune-Inflammatory Responses: Implications beyond Cardiovascular Diseases. <i>Cells</i> , 2021, 10, 1061.	4.1	23
286	Lipid-lowering therapy and low-density lipoprotein cholesterol goal achievement in patients with acute coronary syndromes: The ACS patient pathway project. <i>Atherosclerosis Supplements</i> , 2020, 42, e49-e58.	1.2	23
287	Class II Phosphoinositide 3-Kinases Contribute to Endothelial Cells Morphogenesis. <i>PLoS ONE</i> , 2013, 8, e53808.	2.5	23
288	Monoclonal Antibodies in the Management of Familial Hypercholesterolemia: Focus on PCSK9 and ANGPTL3 Inhibitors. <i>Current Atherosclerosis Reports</i> , 2021, 23, 79.	4.8	23

#	ARTICLE	IF	CITATIONS
289	Familial defective apo B-100, characterization of an Italian family. <i>European Journal of Clinical Investigation</i> , 1991, 21, 389-397.	3.4	22
290	Effect of lacidipine on fatty and proliferative lesions induced in hypercholesterolaemic rabbits. <i>British Journal of Pharmacology</i> , 1996, 118, 215-219.	5.4	22
291	Treatment of severe hypercholesterolemia in apolipoprotein E-deficient mice by intramuscular injection of plasmid DNA. <i>Gene Therapy</i> , 2000, 7, 1795-1801.	4.5	22
292	Effect of ezetimibe/simvastatin versus atorvastatin or rosuvastatin on modifying lipid profiles in patients with diabetes, metabolic syndrome, or neither: Results of two subgroup analyses. <i>Journal of Clinical Lipidology</i> , 2008, 2, 91-105.	1.5	22
293	Proprotein Convertase Subtilisin-Kexin type-9 (PCSK9) and triglyceride-rich lipoprotein metabolism: Facts and gaps. <i>Pharmacological Research</i> , 2018, 130, 1-11.	7.1	22
294	Multifactorial Activation of NLRP3 Inflammasome: Relevance for a Precision Approach to Atherosclerotic Cardiovascular Risk and Disease. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4459.	4.1	22
295	Reduction of Cardio-Metabolic Risk and Body Weight through a Multiphasic Very-Low Calorie Ketogenic Diet Program in Women with Overweight/Obesity: A Study in a Real-World Setting. <i>Nutrients</i> , 2021, 13, 1804.	4.1	22
296	Reduction of Lp(a) plasma levels by bezafibrate. <i>Atherosclerosis</i> , 1993, 100, 127-128.	0.8	21
297	Dual effects of the antioxidant agents probucol and carvedilol on proliferative and fatty lesions in hypercholesterolemic rabbits. <i>Atherosclerosis</i> , 1998, 141, 45-51.	0.8	21
298	Combination therapy in cholesterol reduction: focus on ezetimibe and statins. <i>Vascular Health and Risk Management</i> , 2008, Volume 4, 267-278.	2.3	21
299	HDL and adaptive immunity: A tale of lipid rafts. <i>Atherosclerosis</i> , 2012, 225, 34-35.	0.8	21
300	Association between OLR1 K167N SNP and Intima Media Thickness of the Common Carotid Artery in the General Population. <i>PLoS ONE</i> , 2012, 7, e31086.	2.5	21
301	Fibronectin extra domain A stabilises atherosclerotic plaques in apolipoprotein E and in LDL-receptor-deficient mice. <i>Thrombosis and Haemostasis</i> , 2015, 114, 186-197.	3.4	21
302	Practical aspects in the management of statin-associated muscle symptoms (SAMS). <i>Atherosclerosis Supplements</i> , 2017, 26, 45-55.	1.2	21
303	Pitavastatin and HDL: Effects on plasma levels and function(s). <i>Atherosclerosis Supplements</i> , 2017, 27, e1-e9.	1.2	21
304	Detection of familial hypercholesterolemia in patients from a general practice database. <i>Atherosclerosis Supplements</i> , 2017, 29, 25-30.	1.2	21
305	Use of proton pump inhibitors and risk of ischemic events in the general population. <i>Atherosclerosis</i> , 2018, 277, 123-129.	0.8	21
306	Reported muscle symptoms during statin treatment amongst Italian dyslipidaemic patients in the real-life setting: the PROSISA Study. <i>Journal of Internal Medicine</i> , 2021, 290, 116-128.	6.0	21

#	ARTICLE	IF	CITATIONS
307	Monoclonal antibodies to human low density lipoprotein identify distinct areas on apolipoprotein B-100 relevant to the low density lipoprotein-receptor interaction.. <i>Journal of Lipid Research</i> , 1992, 33, 1111-1121.	4.2	21
308	Antioxidants and coronary artery disease. <i>Current Opinion in Lipidology</i> , 1998, 9, 541-549.	2.7	21
309	Plasma lipoproteins and cholesterol metabolism in Yoshida rats: An animal model of spontaneous hyperlipemia. <i>Life Sciences</i> , 1992, 50, 1913-1924.	4.3	20
310	The CD1d-Natural Killer T Cell Axis in Atherosclerosis. <i>Journal of Innate Immunity</i> , 2014, 6, 3-12.	3.8	20
311	Statin use and risk of cataract: A nested case-control study within a healthcare database. <i>Atherosclerosis</i> , 2016, 251, 153-158.	0.8	20
312	Sex-differences in factors and outcomes associated with adherence to statin therapy in primary care: Need for customisation strategies. <i>Pharmacological Research</i> , 2020, 155, 104514.	7.1	20
313	High density lipoproteins and atherosclerosis: emerging aspects. <i>Journal of Geriatric Cardiology</i> , 2013, 9, 401-407.	0.2	20
314	Efficacy and safety of bempedoic acid in patients not receiving statins in phase 3 clinical trials. <i>Journal of Clinical Lipidology</i> , 2022, 16, 286-297.	1.5	20
315	High-potency statins increase the risk of acute kidney injury: Evidence from a large population-based study. <i>Atherosclerosis</i> , 2014, 234, 224-229.	0.8	19
316	Impact of substitution among generic drugs on persistence and adherence: A retrospective claims data study from 2 Local Healthcare Units in the Lombardy Region of Italy. <i>Atherosclerosis Supplements</i> , 2016, 21, 1-8.	1.2	19
317	Identification and Management of Statin-Associated Symptoms in Clinical Practice: Extension of a Clinician Survey to 12 Further Countries. <i>Cardiovascular Drugs and Therapy</i> , 2017, 31, 187-195.	2.6	19
318	Low Plasma Lecithin: Cholesterol Acyltransferase (LCAT) Concentration Predicts Chronic Kidney Disease. <i>Journal of Clinical Medicine</i> , 2020, 9, 2289.	2.4	19
319	ANMCO/ISS/AMD/ANCE/ARCA/FADOI/GICR-IACPR/SICI-GISE/SIBioC/SIC/SICOA/SID/SIF/SIMEU/SIMG/SIMI/SISA Joint Consensus Document on cholesterol and cardiovascular risk: diagnostic and therapeutic pathway in Italy. <i>European Heart Journal Supplements</i> , 2017, 19, D3-D54.	0.1	19
320	Adherence to the Mediterranean Diet: Impact of Geographical Location of the Observations. <i>Nutrients</i> , 2022, 14, 2040.	4.1	19
321	Effect of the apolipoprotein C-II-C-III1 ratio on the capacity of purified milk lipoprotein lipase to hydrolyse triglycerides in monolayer vesicles. <i>Atherosclerosis</i> , 1996, 127, 205-212.	0.8	18
322	NK-104, a potent 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, decreases apolipoprotein B-100 secretion from Hep G2 cells. <i>Atherosclerosis</i> , 1999, 145, 87-95.	0.8	18
323	Overexpression of Inducible Heat Shock Protein 70 in COS-1 Cells Fails to Protect From Cytotoxicity of Oxidized LDLs. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2001, 21, 348-354.	2.4	18
324	Modification of HDL3 by mild oxidative stress increases ATP-binding cassette transporter 1-mediated cholesterol efflux. <i>Cardiovascular Research</i> , 2007, 75, 566-574.	3.8	18

#	ARTICLE	IF	CITATIONS
325	Cholesterol membrane content has a ubiquitous evolutionary function in immune cell activation: the role of HDL. <i>Current Opinion in Lipidology</i> , 2019, 30, 462-469.	2.7	18
326	The prevalence of cardiovascular risk factors and cardiovascular disease among primary care patients in Poland: results from the LIPIDOGram2015 study. <i>Atherosclerosis Supplements</i> , 2020, 42, e15-e24.	1.2	18
327	Lipid-lowering and anti-thrombotic therapy in patients with peripheral arterial disease. <i>Vasa - European Journal of Vascular Medicine</i> , 2021, 50, 401-411.	1.4	18
328	Decreased intracellular degradation and increased secretion of apo B-100 in Hep G2 cells after inhibition of cholesteryl ester synthesis. <i>Atherosclerosis</i> , 1997, 130, 143-152.	0.8	17
329	Improvement of endothelial function in uraemic patients on peritoneal dialysis: a possible role for 5-MTHF administration. <i>Nephrology Dialysis Transplantation</i> , 2007, 22, 3292-3297.	0.7	17
330	A New Case of Familial LCAT Deficiency. <i>Acta Medica Scandinavica</i> , 1983, 214, 173-176.	0.0	17
331	Homozygous familial hypobetalipoproteinemia: Two novel mutations in the splicing sites of apolipoprotein B gene and review of the literature. <i>Atherosclerosis</i> , 2015, 239, 209-217.	0.8	17
332	Functional Analysis of a Carotid Intima-Media Thickness Locus Implicates <i>BCAR1</i> and Suggests a Causal Variant. <i>Circulation: Cardiovascular Genetics</i> , 2015, 8, 696-706.	5.1	17
333	New strategies for the development of lipid-lowering therapies to reduce cardiovascular risk. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2018, 4, 119-127.	3.0	17
334	Reprint of: Impact of Lipids on Cardiovascular Health. <i>Journal of the American College of Cardiology</i> , 2018, 72, 2980-2995.	2.8	17
335	Evaluation of contemporary treatment of high- and very high-risk patients for the prevention of cardiovascular events in Europe – Methodology and rationale for the multinational observational SANTORINI study. <i>Atherosclerosis Plus</i> , 2021, 43, 24-30.	0.7	17
336	Immunochemical characterization of six monoclonal antibodies to human apolipoprotein A-I: epitope mapping and expression.. <i>Journal of Lipid Research</i> , 1990, 31, 375-384.	4.2	17
337	A study of the structure of the gene for lecithin: Cholesterol acyltransferase in four unrelated individuals with familial lecithin: Cholesterol acyltransferase deficiency. <i>Clinical Science</i> , 1988, 74, 91-96.	4.3	16
338	Poor response to simvastatin in familial defective apo-B-100. <i>Lancet, The</i> , 1991, 337, 305.	13.7	16
339	Oxidized Lipoproteins and Endothelium. <i>Clinical Chemistry and Laboratory Medicine</i> , 2000, 38, 155-60.	2.3	16
340	Title is missing!. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2003, 10, 181-189.	1.5	16
341	Gut Microbiota Functional Dysbiosis Relates to Individual Diet in Subclinical Carotid Atherosclerosis. <i>Nutrients</i> , 2021, 13, 304.	4.1	16
342	Effect of Lipids and Lipoproteins on Hematopoietic Cell Metabolism and Commitment in Atherosclerosis. <i>Immunometabolism</i> , 2021, 3, e210014.	1.6	16

#	ARTICLE	IF	CITATIONS
343	Impact of metabolic disorders on the structural, functional, and immunological integrity of the blood-brain barrier: Therapeutic avenues. <i>FASEB Journal</i> , 2022, 36, e22107.	0.5	16
344	BINDING-DEFECTIVE LOW-DENSITY LIPOPROTEIN IN FAMILY WITH HYPERCHOLESTEROLAEMIA. <i>Lancet</i> , The, 1989, 333, 623.	13.7	15
345	Native LDL and Oxidized LDL modulate cyclooxygenase-2 expression in HUVECs through a p38-MAPK, NF- κ B, CRE dependent pathway and affect PGE2 synthesis. <i>International Journal of Molecular Medicine</i> , 2004, 14, 353-9.	4.0	15
346	Synthesis and Biological Evaluation of Azido- and Aziridino-hydroxyl- β -lactams through Stereo- and Regioselective Epoxide Ring Opening. <i>Journal of Organic Chemistry</i> , 2006, 71, 9229-9232.	3.2	15
347	Prevalence of classical CD14 ⁺⁺ /CD16 ⁺ but not of intermediate CD14 ⁺⁺ /CD16 ⁺ monocytes in hypoalphalipoproteinemia. <i>International Journal of Cardiology</i> , 2013, 168, 2886-2889.	1.7	15
348	Clinical significance of diabetes likely induced by statins: Evidence from a large population-based cohort. <i>Diabetes Research and Clinical Practice</i> , 2017, 133, 60-68.	2.8	15
349	Comparative in vitro study of the pro-apolipoprotein A-I to apolipoprotein A-I converting activity between normal and Tangier plasma. <i>Journal of Clinical Investigation</i> , 1984, 74, 1098-1103.	8.2	15
350	2016 ESC/EAS GUIDELINES FOR THE MANAGEMENT OF DYSLIPIDAEMIAS. <i>Russian Journal of Cardiology</i> , 2017, , 7-77.	1.4	15
351	Plasma lipoproteins and cholesterol metabolism in spontaneously hyperlipemic rats. <i>Atherosclerosis</i> , 1989, 76, 163-171.	0.8	14
352	Cholesterol stimulation of HDL binding to human endothelial cells EAhy 926 and skin fibroblasts: evidence for a mechanism independent of cellular metabolism. <i>Lipids and Lipid Metabolism</i> , 1991, 1083, 94-100.	2.6	14
353	The effect of gemfibrozil on lipid profile and glucose metabolism in hypertriglyceridaemic well-controlled non-insulin-dependent diabetic patients. <i>Acta Diabetologica</i> , 1999, 36, 27-33.	2.5	14
354	Lipid lowering activity of drugs affecting cholesterol absorption. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2004, 14, 42-51.	2.6	14
355	Reaching LDL-c targets in high-risk patients requires high-efficacy cholesterol-lowering drugs in more than 50% of cases. The results of the CHECK study. <i>Pharmacological Research</i> , 2011, 64, 393-396.	7.1	14
356	Statins decrease thrombin generation in patients with hypercholesterolemia. <i>European Journal of Internal Medicine</i> , 2014, 25, 449-451.	2.2	14
357	Anti-PCSK9 antibodies for the treatment of heterozygous familial hypercholesterolemia: patient selection and perspectives. <i>Vascular Health and Risk Management</i> , 2017, Volume 13, 343-351.	2.3	14
358	Statins increase Lp(a) plasma level: is this clinically relevant?. <i>European Heart Journal</i> , 2020, 41, 2285-2287.	2.2	14
359	Inflammaging and neurodegenerative diseases: Role of NLRP3 inflammasome activation in brain atherosclerotic vascular disease. <i>Mechanisms of Ageing and Development</i> , 2021, 195, 111467.	4.6	14
360	Pharmacodynamic effect of bempedoic acid and statin combinations: predictions from a dose-response model. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 578-586.	3.0	14

#	ARTICLE	IF	CITATIONS
361	PCSK9 promotes arterial medial calcification. <i>Atherosclerosis</i> , 2022, 346, 86-97.	0.8	14
362	Epitope mapping analysis of apolipoprotein B-100 using a surface plasmon resonance-based biosensor. <i>Biosensors and Bioelectronics</i> , 2001, 16, 963-969.	10.1	13
363	ASSET (Age/Sex Standardised Estimates of Treatment): A Research Model to Improve the Governance of Prescribing Funds in Italy. <i>PLoS ONE</i> , 2007, 2, e592.	2.5	13
364	Ezetimibe/simvastatin compared with atorvastatin or rosuvastatin in lowering to specified levels both LDL-C and each of five other emerging risk factors for coronary heart disease: Non-HDL-cholesterol, TC/HDL-C, apolipoprotein B, apo-B/apo-A-I, or C-reactive protein. <i>Journal of Clinical Lipidology</i> , 2008, 2, 436-446.	1.5	13
365	Pitavastatin: a different pharmacological profile. <i>Clinical Lipidology</i> , 2012, 7, 3-9.	0.4	13
366	How many patients need statin treatment in a low-cardiovascular-risk country? Low-density lipoprotein-cholesterol target and distance from target distribution in an Italian cohort. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2012, 22, 327-336.	2.6	13
367	Drug treatment and adherence of subjects <40 years with diagnosis of heterozygous familial hypercholesterolemia. <i>Atherosclerosis</i> , 2016, 254, 172-178.	0.8	13
368	Current guidelines on prevention with a focus on dyslipidemias. <i>Cardiovascular Diagnosis and Therapy</i> , 2017, 67, S4-S10.	1.7	13
369	New prospects for PCSK9 inhibition?. <i>European Heart Journal</i> , 2018, 39, 2600-2601.	2.2	13
370	Metabolic adaptations of cells at the vascular-immune interface during atherosclerosis. <i>Molecular Aspects of Medicine</i> , 2021, 77, 100918.	6.4	13
371	Effects of HDL3 on the expression of matrix-degrading proteases in human endothelial cells. <i>International Journal of Molecular Medicine</i> , 2003, 12, 73-8.	4.0	13
372	Effect of partial ileal bypass on plasma clearance and binding of lipoproteins to liver membranes in the rabbit. <i>Atherosclerosis</i> , 1983, 46, 269-273.	0.8	12
373	Activation of lipoprotein lipase by apolipoprotein C-II is modulated by the COOH terminal region of apolipoprotein C-III. <i>Chemistry and Physics of Lipids</i> , 1987, 45, 39-47.	3.2	12
374	HDL: To Treat or Not To Treat?. <i>Current Atherosclerosis Reports</i> , 2014, 16, 429.	4.8	12
375	Update on the management of severe hypertriglyceridemia – focus on free fatty acid forms of omega-3. <i>Drug Design, Development and Therapy</i> , 2015, 9, 2129.	4.3	12
376	Efficacy of alirocumab according to background statin type and dose: pooled analysis of 8 ODYSSEY Phase 3 clinical trials. <i>Scientific Reports</i> , 2017, 7, 45788.	3.3	12
377	Good adherence to therapy with statins reduces the risk of adverse clinical outcomes even among very elderly. Evidence from an Italian real-life investigation. <i>European Journal of Internal Medicine</i> , 2018, 47, 25-31.	2.2	12
378	LIPA gene mutations affect the composition of lipoproteins: Enrichment in ACAT-derived cholesteryl esters. <i>Atherosclerosis</i> , 2020, 297, 8-15.	0.8	12

#	ARTICLE	IF	CITATIONS
379	Twelve Variants Polygenic Score for Low-Density Lipoprotein Cholesterol Distribution in a Large Cohort of Patients With Clinically Diagnosed Familial Hypercholesterolemia With or Without Causative Mutations. <i>Journal of the American Heart Association</i> , 2022, 11, e023668.	3.7	12
380	Oxysterols from oxidized LDL are cytotoxic but fail to induce hsp70 expression in endothelial cells. <i>FEBS Letters</i> , 1999, 462, 113-116.	2.8	11
381	In Human Endothelial Cells Amino Acids Inhibit Insulin-induced Akt and ERK1/2 Phosphorylation by an mTOR-dependent Mechanism. <i>Journal of Cardiovascular Pharmacology</i> , 2006, 47, 643-649.	1.9	11
382	LOX-1 Inhibition in ApoE KO Mice Using a Schizophyllan-based Antisense Oligonucleotide Therapy. <i>Molecular Therapy - Nucleic Acids</i> , 2012, 1, e58.	5.1	11
383	-374 T/A RAGE Polymorphism Is Associated with Chronic Kidney Disease Progression in Subjects Affected by Nephrocardiovascular Disease. <i>PLoS ONE</i> , 2013, 8, e60089.	2.5	11
384	Association between the cumulative exposure to bisphosphonates and hospitalization for atherosclerotic cardiovascular events: A population-based study. <i>Atherosclerosis</i> , 2020, 301, 1-7.	0.8	11
385	LDL-cholesterol lowering and clinical outcomes in hypercholesterolemic subjects with and without a familial hypercholesterolemia phenotype: Analysis from the secondary prevention 4S trial. <i>Atherosclerosis</i> , 2021, 320, 1-9.	0.8	11
386	New insights into the role of bempedoic acid and ezetimibe in the treatment of hypercholesterolemia. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2022, 29, 161-166.	2.3	11
387	Oxidized-HDL3 modulates the expression of Cox-2 in human endothelial cells. <i>International Journal of Molecular Medicine</i> , 2006, 18, 209-13.	4.0	11
388	The low density lipoprotein receptor: Structure, function and pharmacological modulation. , 1989, 43, 187-219.		10
389	Bridging science and health policy in cardiovascular disease: focus on lipid management. <i>Atherosclerosis Supplements</i> , 2009, 10, 3-21.	1.2	10
390	Dual effect of hypochlorite in the modification of high density lipoproteins. <i>Biochemical and Biophysical Research Communications</i> , 2010, 403, 447-451.	2.1	10
391	IDOL N342S Variant, Atherosclerosis Progression and Cardiovascular Disorders in the Italian General Population. <i>PLoS ONE</i> , 2015, 10, e0122414.	2.5	10
392	Think Again About Cholesterol Survey. <i>Atherosclerosis Supplements</i> , 2015, 20, 1-5.	1.2	10
393	PCSK9 inhibition and Lp(a) reduction: another piece of the puzzle?. <i>European Heart Journal</i> , 2018, 39, 2586-2588.	2.2	10
394	Progression of conventional cardiovascular risk factors and vascular disease risk in individuals: insights from the PROG-IMT consortium. <i>European Journal of Preventive Cardiology</i> , 2020, 27, 234-243.	1.8	10
395	Omega-3 for Cardiovascular Diseases: Where Do We Stand After REDUCE-IT and STRENGTH?. <i>Circulation</i> , 2021, 144, 183-185.	1.6	10
396	Integrative Analysis of Multi-Omics and Genetic Approaches – A New Level in Atherosclerotic Cardiovascular Risk Prediction. <i>Biomolecules</i> , 2021, 11, 1597.	4.0	10

#	ARTICLE	IF	CITATIONS
397	How registers could enhance knowledge and characterization of genetic dyslipidaemias: The experience of the LIPIGEN in Italy and of other networks for familial hypercholesterolemia. <i>Atherosclerosis Supplements</i> , 2020, 42, e35-e40.	1.2	10
398	Evaluation of apolipoproteins A-I and B as markers of angiographically assessed coronary artery disease. <i>Research in Clinic and Laboratory</i> , 1988, 18, 319-328.	0.3	9
399	Effects of coffee on plasma lipids, lipoproteins and apolipoproteins. <i>Pharmacological Research</i> , 1989, 21, 27-38.	7.1	9
400	Hypobetalipoproteinemia associated with apo B-48.4, a truncated protein only 14 amino acids longer than apo B-48. <i>Atherosclerosis</i> , 1998, 137, 125-131.	0.8	9
401	Triglyceride-Rich Lipoproteins From Normotriglyceridemic Subjects and Hyperlipidemic Patients Differently Affect Endothelial Cell Activation and Gene Expression Patterns. <i>Circulation Research</i> , 2007, 100, e81.	4.5	9
402	Low-Density Lipoprotein Cholesterol Reduction and Goal Achievement With Ezetimibe/Simvastatin Versus Atorvastatin or Rosuvastatin in Patients With Diabetes, Metabolic Syndrome, or Neither Disease, Stratified by National Cholesterol Education Program Risk Category. <i>Metabolic Syndrome and Related Disorders</i> , 2009, 7, 601-610.	1.3	9
403	Leonurine: A new comer in the natural compounds affecting atherosclerosis. <i>Atherosclerosis</i> , 2012, 224, 37-38.	0.8	9
404	Effect of Tie-2 conditional deletion of BDNF on atherosclerosis in the ApoE null mutant mouse. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2012, 1822, 927-935.	3.8	9
405	15- α -Lipoxygenase-Mediated Modification of HDL ³ Impairs eNOS Activation in Human Endothelial Cells. <i>Lipids</i> , 2014, 49, 317-326.	1.7	9
406	Incretin-based drugs and risk of acute pancreatitis: A nested-case control study within a healthcare database. <i>Diabetes Research and Clinical Practice</i> , 2015, 108, 243-249.	2.8	9
407	Pharmaceutical strategies for reducing LDL-C and risk of cardiovascular disease. <i>Atherosclerosis: X</i> , 2019, 39, 100002.	0.0	9
408	Omega n-3 Supplementation: Exploring the Cardiovascular Benefits Beyond Lipoprotein Reduction. <i>Current Atherosclerosis Reports</i> , 2020, 22, 74.	4.8	9
409	Lipid Clinics Network. Rationale and design of the EAS global project. <i>Atherosclerosis Supplements</i> , 2020, 42, e6-e8.	1.2	9
410	Lower Rate of Cardiovascular Complications in Patients on Bolus Insulin Analogues: A Retrospective Population-Based Cohort Study. <i>PLoS ONE</i> , 2013, 8, e79762.	2.5	9
411	Design and rationale of a nationwide screening analysis from the LIPIDOGRAM2015 and LIPIDOGEN2015 studies. <i>Archives of Medical Science</i> , 2020, 18, 604-616.	0.9	9
412	The Differences in the Prevalence of Cardiovascular Disease, Its Risk Factors, and Achievement of Therapeutic Goals among Urban and Rural Primary Care Patients in Poland: Results from the LIPIDOGRAM 2015 Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 5656.	2.4	9
413	Apolipoprotein C-II and lipoprotein lipase activity. <i>Research in Clinic and Laboratory</i> , 1982, 12, 35-40.	0.3	9
414	The year in cardiovascular medicine 2021: dyslipidaemia. <i>European Heart Journal</i> , 2022, , .	2.2	9

#	ARTICLE	IF	CITATIONS
415	Nutraceuticals for Dyslipidaemia and Glucometabolic Diseases: What the Guidelines Tell Us (and Do) Tj ETQq1 1 0.784314 rgBT /Over	4.1	9
416	The zebrafish model system for dyslipidemia and atherosclerosis research: Focus on environmental/exposome factors and genetic mechanisms. <i>Metabolism: Clinical and Experimental</i> , 2022, 129, 155138.	3.4	9
417	How should public health recommendations address Lp(a) measurement, a causative risk factor for cardiovascular disease (CVD)?. <i>Atherosclerosis</i> , 2022, 349, 136-143.	0.8	9
418	Predictive value of HDL function in patients with coronary artery disease: relationship with coronary plaque characteristics and clinical events. <i>Annals of Medicine</i> , 2022, 54, 1036-1046.	3.8	9
419	Lipoprotein(a) and family history for cardiovascular disease in paediatric patients: A new frontier in cardiovascular risk stratification. Data from the LIPIGEN paediatric group. <i>Atherosclerosis</i> , 2022, 349, 233-239.	0.8	9
420	Effects of probucol on the in vivo plasma clearance of human low density lipoproteins in rabbits and on the expression of lipoprotein receptors in vitro. <i>Atherosclerosis</i> , 1984, 52, 309-316.	0.8	8
421	Monitoring statin safety in primary care. <i>Pharmacoepidemiology and Drug Safety</i> , 2007, 16, 652-657.	1.9	8
422	Residual cardiovascular risk. <i>European Heart Journal Supplements</i> , 2016, 18, C1-C1.	0.1	8
423	Why is hypercholesterolaemia so prevalent? A view from evolutionary medicine. <i>European Heart Journal</i> , 2019, 40, 2825-2830.	2.2	8
424	Beyond LDL-C levels, does remnant cholesterol estimation matter?. <i>European Journal of Preventive Cardiology</i> , 2020, 27, 1088-1090.	1.8	8
425	LDL-Cholesterol-Lowering Therapy. <i>Handbook of Experimental Pharmacology</i> , 2020, , 1.	1.8	8
426	Current perceptions and practices in lipid management: results of a European Society of Cardiology/European Atherosclerosis Society Survey. <i>European Journal of Preventive Cardiology</i> , 2022, 28, 2030-2037.	1.8	8
427	Taking action: European Atherosclerosis Society targets the United Nations Sustainable Development Goals 2030 agenda to fight atherosclerotic cardiovascular disease in Europe. <i>Atherosclerosis</i> , 2021, 322, 77-81.	0.8	8
428	Prevalence Of familial hypercholeSTerolaemia (FH) in Italian Patients with coronary artERY disease: The POSTER study. <i>Atherosclerosis</i> , 2020, 308, 32-38.	0.8	8
429	Improving lipid management in patients with acute coronary syndrome: The ACS Lipid EuroPath tool. <i>Atherosclerosis Supplements</i> , 2020, 42, e65-e71.	1.2	8
430	Implementation of clinical practices and pathways optimizing ACS patients lipid management: Focus on eight European initiatives. <i>Atherosclerosis Supplements</i> , 2020, 42, e59-e64.	1.2	8
431	Prevalence and relationship between metabolic syndrome and risk of cardiovascular disease: Evidence from two population-based studies. <i>Atherosclerosis Supplements</i> , 2020, 42, e41-e48.	1.2	8
432	Lipid-lowering and anti-thrombotic therapy in patients with peripheral arterial disease. <i>Atherosclerosis</i> , 2021, 338, 55-63.	0.8	8

#	ARTICLE	IF	CITATIONS
433	Glycosaminoglycans and lipoprotein metabolism: An overview. <i>Pharmacological Research Communications</i> , 1979, 11, 571-583.	0.2	7
434	Experimental studies on the hypolipidemic activity of chloridarol. <i>Pharmacological Research Communications</i> , 1983, 15, 201-215.	0.2	7
435	Effects of insulin deficiency on the catabolism of plasma lipoproteins and on the expression of hepatic lipoprotein receptors in rats. <i>Pharmacological Research Communications</i> , 1984, 16, 539-548.	0.2	7
436	Immunoreactivity of apo B towards monoclonal antibodies that inhibit the LDL-receptor interaction: effects of LDL oxidation. <i>Atherosclerosis</i> , 1993, 101, 37-41.	0.8	7
437	A new case of apo C-II deficiency with a nonsense mutation in the apo C-II gene. <i>Clinica Chimica Acta</i> , 1994, 224, 111-118.	1.1	7
438	Oxidized-HDL3 modulates the expression of Cox-2 in human endothelial cells. <i>International Journal of Molecular Medicine</i> , 2006, 18, 209.	4.0	7
439	Effect on Fasting Serum Glucose Levels of Adding Ezetimibe to Statins in Patients With Nondiabetic Hypercholesterolemia. <i>American Journal of Cardiology</i> , 2016, 118, 1812-1820.	1.6	7
440	Potential utility of the SAFEHEART risk equation for rationalising the use of PCSK9 monoclonal antibodies in adults with heterozygous familial hypercholesterolemia. <i>Atherosclerosis</i> , 2019, 286, 40-45.	0.8	7
441	Efficacy and safety of bempedoic acid in patients with heterozygous familial hypercholesterolemia: Analysis of pooled patient-level data from phase 3 clinical trials. <i>Atherosclerosis</i> , 2020, 315, e12-e13.	0.8	7
442	A Synthetic Peptide Designed to Neutralize Lipopolysaccharides Attenuates Metaflammation and Diet-Induced Metabolic Derangements in Mice. <i>Frontiers in Immunology</i> , 2021, 12, 701275.	4.8	7
443	Refinement of pathogenicity classification of variants associated with familial hypercholesterolemia: Implications for clinical diagnosis. <i>Journal of Clinical Lipidology</i> , 2021, 15, 822-831.	1.5	7
444	Recent insights into low-density lipoprotein metabolism and therapy. <i>Current Opinion in Clinical Nutrition and Metabolic Care</i> , 2021, 24, 120-126.	2.5	7
445	Pharmacological studies on tiadenol in type IV patients Evidence for a mechanism of action different from other lipid-lowering drugs. <i>Atherosclerosis</i> , 1981, 40, 245-255.	0.8	6
446	Progesterone modulates the expression of HDL binding sites in human skin fibroblasts. <i>Atherosclerosis</i> , 1988, 74, 107-113.	0.8	6
447	SIM 6080, A New Calcium Antagonist, Reduces Aortic Atherosclerosis in Cholesterol-Fed Rabbits. <i>Pharmacological Research</i> , 1993, 28, 219-228.	7.1	6
448	Antioxidants and coronary artery disease. <i>Current Atherosclerosis Reports</i> , 1999, 1, 221-229.	4.8	6
449	A successful dietary treatment fails to normalize plasma triglyceride postprandial response in type IV patients. <i>Atherosclerosis</i> , 1999, 146, 19-23.	0.8	6
450	Statins and Oxidative Stress During Atherogenesis. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2003, 10, 181-189.	2.8	6

#	ARTICLE	IF	CITATIONS
451	Effects of HDL3 on the expression of matrix-degrading proteases in human endothelial cells. <i>International Journal of Molecular Medicine</i> , 2003, 12, 73.	4.0	6
452	The pharmacologic elegance of inhibiting cholesterol absorption and synthesis while providing a homeostatic balance. <i>Fundamental and Clinical Pharmacology</i> , 2007, 21, 21-26.	1.9	6
453	Epidemiology of cardiovascular risk factors in two population-based studies. <i>Atherosclerosis Supplements</i> , 2018, 35, e14-e20.	1.2	6
454	Can EPA evaporate plaques?. <i>European Heart Journal</i> , 2020, 41, 3933-3935.	2.2	6
455	Insights from ORION studies: focus on inclisiran safety. <i>Cardiovascular Research</i> , 2021, 117, 24-26.	3.8	6
456	Interactions of Oxysterols with Atherosclerosis Biomarkers in Subjects with Moderate Hypercholesterolemia and Effects of a Nutraceutical Combination (Bifidobacterium longum BB536, Red) Tj ETQq0 0.0 rgBT /Overlock 10	0.0	6
457	Hypercholesterolemia and cardiovascular disease: Focus on high cardiovascular risk patients. <i>Atherosclerosis Supplements</i> , 2020, 42, e30-e34.	1.2	6
458	Cholesterol Lowering Biotechnological Strategies: From Monoclonal Antibodies to Antisense Therapies. A Pre-Clinical Perspective Review. <i>Cardiovascular Drugs and Therapy</i> , 2023, 37, 585-598.	2.6	6
459	Implications of ACC/AHA Versus ESC/EAS LDL-C Recommendations for Residual Risk Reduction in ASCVD: A Simulation Study From ADA VINCI. <i>Cardiovascular Drugs and Therapy</i> , 2023, 37, 941-953.	2.6	6
460	Evinacumab: a new option in the treatment of homozygous familial hypercholesterolemia. <i>Expert Opinion on Biological Therapy</i> , 2022, 22, 813-820.	3.1	6
461	ApoE gene delivery inhibits severe hypercholesterolemia in newborn ApoE-KO mice. <i>Biochemical and Biophysical Research Communications</i> , 2007, 361, 543-548.	2.1	5
462	Guidelines on CVD prevention: Confusing or complementary?. <i>Atherosclerosis</i> , 2013, 226, 299-300.	0.8	5
463	A simple informative intervention in primary care increases statin adherence. <i>European Journal of Clinical Pharmacology</i> , 2016, 72, 227-234.	1.9	5
464	Proprotein Convertase Subtilisin Kexin 9 Inhibitors. <i>Cardiology Clinics</i> , 2018, 36, 241-256.	2.2	5
465	Lifestyle interventions and nutraceuticals: Guideline-based approach to cardiovascular disease prevention. <i>Atherosclerosis: X</i> , 2019, 1, 100003.	0.0	5
466	Increasing high-density lipoprotein cholesterol levels for cardiovascular benefit: The end of a dream?. <i>European Journal of Preventive Cardiology</i> , 2019, 26, 531-532.	1.8	5
467	Worldwide Changes in Total Cholesterol and Non-HDL-Cholesterol Trends Indicate Where the Challenges Are for the Coming Years. <i>Clinical Chemistry</i> , 2021, 67, 30-32.	3.2	5
468	Similarities and differences between European and American guidelines on the management of blood lipids to reduce cardiovascular risk. <i>Atherosclerosis Supplements</i> , 2020, 42, e1-e5.	1.2	5

#	ARTICLE	IF	CITATIONS
469	Molecular Immune-Inflammatory Connections between Dietary Fats and Atherosclerotic Cardiovascular Disease: Which Translation into Clinics?. <i>Nutrients</i> , 2021, 13, 3768.	4.1	5
470	Genetically determined hypercholesterolaemia results into premature leucocyte telomere length shortening and reduced haematopoietic precursors. <i>European Journal of Preventive Cardiology</i> , 2022, 29, 721-729.	1.8	5
471	Analysis of the impact of sex and age on the variation in the prevalence of antinuclear autoantibodies in Polish population: a nationwide observational, cross-sectional study. <i>Rheumatology International</i> , 2022, 42, 261-271.	3.0	5
472	Prevention guidelines and EAS/ESC guidelines for the treatment of dyslipidaemias: A look to the future. <i>Atherosclerosis</i> , 2022, 340, 51-52.	0.8	5
473	Targeted Plasma Proteomics to Predict the Development of Carotid Plaques. <i>Stroke</i> , 2022, 53, .	2.0	5
474	Cholesterol feeding to rats does not modulate the expression of binding sites for HDL on liver membranes. <i>Experientia</i> , 1986, 42, 1155-1157.	1.2	4
475	Monoclonal antibody 5A binds apolipoprotein B-48 and inhibits the low density lipoprotein-receptor interaction. <i>Biochemical and Biophysical Research Communications</i> , 1989, 162, 908-915.	2.1	4
476	Blood pressure and antihypertensive therapy according to the global cardiovascular risk level in Italy: the CHECK Study. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2010, 17, 562-568.	2.8	4
477	C-reactive protein distribution and correlation with traditional cardiovascular risk factors in the Italian population. <i>European Journal of Internal Medicine</i> , 2013, 24, 161-166.	2.2	4
478	Corrigendum to "Long-term effect of high dose omega-3 fatty acid supplementation for secondary prevention of cardiovascular outcomes: A meta-analysis of randomized, double blind, placebo controlled trials" [Atheroscler Suppl 14 (2) (2013) 243-251]. <i>Atherosclerosis</i> , 2014, 233, 122.	0.8	4
479	Statin use and risk of new-onset diabetes: a meta-analysis of observational studies. <i>Atherosclerosis</i> , 2017, 263, e262-e263.	0.8	4
480	The challenge of risk prediction: How good are we?. <i>European Journal of Preventive Cardiology</i> , 2018, 25, 418-419.	1.8	4
481	Treatment with fibrates is associated with higher LAL activity in dyslipidemic patients. <i>Pharmacological Research</i> , 2019, 147, 104362.	7.1	4
482	Understanding the Patient Perception of Statin Experience: A Qualitative Study. <i>Advances in Therapy</i> , 2019, 36, 2723-2743.	2.9	4
483	Transatlantic Lipid Guideline Divergence: Same Data But Different Interpretations. <i>Journal of the American Heart Association</i> , 2020, 9, e018189.	3.7	4
484	A pragmatic controlled trial to improve the appropriate prescription of drugs in adult outpatients: design and rationale of the EDU.RE.DRUG study. <i>Primary Health Care Research and Development</i> , 2020, 21, .	1.2	4
485	The Prospective Studies of Atherosclerosis (Proof-ATHERO) Consortium: Design and Rationale. <i>Gerontology</i> , 2020, 66, 447-459.	2.8	4
486	Lipoprotein remnants: to be or not to be. <i>European Heart Journal</i> , 2021, 42, 4844-4846.	2.2	4

#	ARTICLE	IF	CITATIONS
487	One year after the ESC/EAS guidelines on cholesterol control. What's the new evidence? What's missing?. <i>European Journal of Internal Medicine</i> , 2022, 95, 1-4.	2.2	4
488	The Role of Registers in Increasing Knowledge and Improving Management of Children and Adolescents Affected by Familial Hypercholesterolemia: the LIPIGEN Pediatric Group. <i>Frontiers in Genetics</i> , 0, 13, .	2.3	4
489	A new fluorometric method for measuring the action of C apolipoproteins on milk lipoprotein lipase. <i>Clinica Chimica Acta</i> , 1997, 264, 75-90.	1.1	3
490	Heart Protection Study. <i>Lancet</i> , The, 2003, 361, 528.	13.7	3
491	Cholesterol control in stroke prevention in Italy: a cross-sectional study in family practice. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2005, 12, 159-163.	2.8	3
492	HDL and endothelial function: from molecular mechanisms to clinical observations. <i>Future Lipidology</i> , 2006, 1, 343-355.	0.5	3
493	Statins and periodontal inflammation: A pleiotropic effect of statins or a pleiotropic effect of LDL-cholesterol lowering?. <i>Atherosclerosis</i> , 2014, 234, 381-382.	0.8	3
494	Atherogenic lipoproteins as treatment targets. <i>Nature Reviews Cardiology</i> , 2018, 15, 75-76.	13.7	3
495	Atherogenic markers in predicting cardiovascular risk and targeting residual cardiovascular risk. <i>Atherosclerosis: X</i> , 2019, 1, 100001.	0.0	3
496	High-density lipoprotein cholesterol levels, cardiovascular disease risk, and cancer: a relation which does not apply to all?. <i>Cardiovascular Research</i> , 2019, 115, 6-7.	3.8	3
497	The cardiovascular benefit of Lp(a) reduction: not there yet. <i>European Heart Journal</i> , 2020, 41, 4256-4258.	2.2	3
498	Balancing cardiovascular benefit and diabetogenic harm of therapy with statins: Real-world evidence from Italy. <i>Diabetes Research and Clinical Practice</i> , 2020, 164, 108197.	2.8	3
499	TRIMETAZIDINE COUNTERACTS TACROLIMUS NEPHROTOXICITY IN A HYPERTENSIVE LIVER TRANSPLANT PATIENT. <i>Transplantation</i> , 1999, 68, 1211.	1.0	3
500	Risk factors distribution and cardiovascular disease prevalence in the Italian population: The CHECK study. <i>Open Journal of Epidemiology</i> , 2012, 02, 90-100.	0.4	3
501	New and Emerging Therapies for Dyslipidemia. <i>Endocrinology and Metabolism Clinics of North America</i> , 2022, , .	3.2	3
502	Effect of bezafibrate on plasma lipid in a strain of genetically hypercholesterolemic rco rats. <i>Pharmacological Research</i> , 1989, 21, 109-110.	7.1	2
503	Molecular Mechanisms Responsible for the Anti-Inflammatory and Protective Effect of High-Density Lipoprotein on the Endothelium. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2007, 14, 21-31.	2.2	2
504	Guidelines on CVD prevention: confusing or complementary?. <i>European Journal of Preventive Cardiology</i> , 2013, 20, 6-8.	1.8	2

#	ARTICLE	IF	CITATIONS
505	Production and Metabolism of Triglyceride-Rich Lipoproteins in Both the Normal and Diabetic States. <i>Contemporary Diabetes</i> , 2014, , 125-139.	0.0	2
506	Comment to the position paper on global recommendations for the management of dyslipidemia developed by the International Atherosclerosis Society (IAS). <i>Atherosclerosis</i> , 2014, 233, 508-509.	0.8	2
507	Leukocyte telomere length, genetically determined, is causally associated with the progression of carotid Intima-Media Thickness and incidence of cardiovascular events. <i>Atherosclerosis</i> , 2016, 252, e252.	0.8	2
508	Genetically determined telomeres shortening is associated with carotid atherosclerosis progression and increased incidence of cardiovascular events. <i>International Journal of Cardiology</i> , 2016, 223, 43-45.	1.7	2
509	Management of Dyslipidemias in Europe and the USA: Same Evidence, Different Conclusions? Can We Find Common Ground?. <i>Current Cardiology Reports</i> , 2017, 19, 49.	2.9	2
510	Strategies for the use of nonstatin therapies. <i>Current Opinion in Lipidology</i> , 2017, 28, 458-464.	2.7	2
511	Automatic identification of variables in epidemiological datasets using logic regression. <i>BMC Medical Informatics and Decision Making</i> , 2017, 17, 40.	3.0	2
512	A mendelian randomization study comparing the effect of low-density lipoproteins and triglyceride-rich very low-density lipoproteins on the risk of coronary heart disease. <i>Atherosclerosis</i> , 2018, 275, e78-e79.	0.8	2
513	Progress and prospects of biological approaches targeting PCSK9 for cholesterol-lowering, from molecular mechanism to clinical efficacy. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 1477-1489.	3.1	2
514	Bempedoic Acid and Glycemic Control: A Pooled Analysis of 4 Phase 3 Clinical Trials. <i>Journal of Clinical Lipidology</i> , 2020, 14, 577-579.	1.5	2
515	Serum antinuclear autoantibodies are associated with measures of oxidative stress and lifestyle factors: analysis of LIPIDOGRAM2015 and LIPIDOGEM2015 studies. <i>Archives of Medical Science</i> , 2023, 19, 1214-1227.	0.9	2
516	Secondary Stroke Prevention in Polish Adults: Results from the LIPIDOGRAM2015 Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 4472.	2.4	2
517	Cholesterol control in stroke prevention in Italy: a cross-sectional study in family practice. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2005, 12, 159-163.	2.8	2
518	Averting a pandemic health crisis in Europe by 2020: what physicians need to know regarding cholesterol management. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2007, 14, 340-345.	2.8	2
519	Statins and Lomitapide: A Suitable Response for Homozygous Familial Hypercholesterolemia?. , 2015, , 87-97.		2
520	â€Diet and lifestyleâ€™ in the management of dyslipidaemia and prevention of CVD - Understanding the level of knowledge and interest of European Atherosclerosis Society members. <i>Atherosclerosis Supplements</i> , 2020, 42, e9-e14.	1.2	2
521	Understanding the efficacy and safety of lomitapide in homozygous familial hypercholesterolaemia. <i>European Journal of Preventive Cardiology</i> , 2022, 29, 829-831.	1.8	2
522	Potentially Inappropriate Prescribing among Elderly Outpatients: Evaluation of Temporal Trends 2012â€2018 in Piedmont, Italy. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 3612.	2.6	2

#	ARTICLE	IF	CITATIONS
523	Reduction of LDL production rate in ileal bypassed rabbits treated with lovastatin. Pharmacological Research, 1991, 23, 129-137.	7.1	1
524	Triglycerides rich lipoproteins and atherosclerosis: in vitro and in vivo studies. International Congress Series, 2004, 1262, 507-510.	0.2	1
525	Secondary prevention of myocardial infarction: a survey in primary care. Journal of Cardiovascular Medicine, 2006, 7, 422-426.	1.5	1
526	Genetic Polymorphisms in an Aged Population. High Blood Pressure and Cardiovascular Prevention, 2007, 14, 99-101.	2.2	1
527	Inhibition of synthesis and absorption of cholesterol: A new option in managing hypercholesterolemia. International Congress Series, 2007, 1303, 121-128.	0.2	1
528	Therapy and clinical trials. Current Opinion in Lipidology, 2011, 22, 324-325.	2.7	1
529	Endothelin-1 does not impair insulin-induced angiogenesis in vitro. International Journal of Molecular Medicine, 2011, 28, 443-8.	4.0	1
530	Plasma proprotein convertase subtilisin kexin type 9 (pcsk9) and plasma lipids in a free living population: results from the plic study. Atherosclerosis, 2014, 235, e60.	0.8	1
531	Introduction. Atherosclerosis Supplements, 2015, 17, 1.	1.2	1
532	Management of Patients with Statin Intolerance in Japan, South Korea and Taiwan: Comparison of Results From A Clinician Survey. Value in Health, 2016, 19, A872.	0.3	1
533	CYP2D6 polymorphism is not associated with altered lipid phenotypes and cimt progression in a PLIC study. Atherosclerosis, 2016, 252, e76.	0.8	1
534	Targeting Cholesterol in Non-ischemic Heart Failure: A Role for LDLR Gene Therapy?. Molecular Therapy, 2017, 25, 2435-2437.	8.2	1
535	The predimed score: index of adherence to the mediterranean diet in the general population: The PLIC study. Atherosclerosis, 2017, 263, e92.	0.8	1
536	Ldl-cholesterol reduction with PCSK9 inhibitors: A meta-analysis of randomised controlled trials. Atherosclerosis, 2017, 263, e244.	0.8	1
537	Advances in Hypercholesterolemia. , 2017, , 663-693.		1
538	PCSK9 deficiency results in altered glucose control and increased ectopic fat accumulation in experimental models and in humans. Atherosclerosis, 2018, 275, e2.	0.8	1
539	Life-Style And Cardio-Metabolic Profile Of A Population Living In A Clustered Alpine Village (The Plic) Tj ETQq1 1 0.784314 rgBT /Overl	0.8	1
540	Lipid Lowering and Incidence of Cataract, a Role for Fibrates. Clinical Pharmacology and Therapeutics, 2019, 105, 318-319.	4.7	1

#	ARTICLE	IF	CITATIONS
541	The year 2019 in Atherosclerosis. <i>Atherosclerosis</i> , 2020, 299, 67-75.	0.8	1
542	Update on Lipids and Lipoproteinsâ€™Reply. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 400.	7.4	1
543	The year 2020 in Atherosclerosis. <i>Atherosclerosis</i> , 2021, 326, 35-44.	0.8	1
544	PCSK9 deficiency and heart metabolism. <i>Atherosclerosis</i> , 2021, 331, e15.	0.8	1
545	185-OR: Efficacy and Safety of Bempedoic Acid in Patients with Diabetes, Prediabetes, and Normoglycemia: Analysis of Pooled Patient-Level Data from Four Phase 3 Clinical Trials. <i>Diabetes</i> , 2020, 69, .	0.6	1
546	Association between the Adherence to AHA Step 1 Nutrition Criteria and the Cardiometabolic Outcome in the General Population a Two Year Follow-Up Study. <i>Food and Nutrition Sciences (Print)</i> , 2012, 03, 274-280.	0.4	1
547	Hypercholesterolemia and cardiovascular disease: What to do before initiating pharmacological therapy. <i>Atherosclerosis Supplements</i> , 2020, 42, e25-e29.	1.2	1
548	Effect of simvastatin in subjects with familial defective apolipoprotein B-100. <i>Pharmacological Research</i> , 1990, 22, 129.	7.1	0
549	Characterization of a family with moderate hypercholesterolemia and binding defective low density lipoprotein. <i>European Journal of Epidemiology</i> , 1992, 8, 26-32.	5.7	0
550	Title is missing!. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2003, 10, 153-154.	1.5	0
551	MTE01-IS-003 LCAT deficiency. <i>Atherosclerosis Supplements</i> , 2005, 6, 181.	1.2	0
552	Global Cardiovascular Risk. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2005, 12, 125-133.	2.2	0
553	Th-P15:199 Modulation of pentraxin 3 expression in endothelial cells: Role of HDL. <i>Atherosclerosis Supplements</i> , 2006, 7, 537.	1.2	0
554	Averting a pandemic health crisis in Europe by 2020: what physicians need to know regarding cholesterol management. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2007, 14, 340-345.	2.8	0
555	Triglyceride-rich lipoproteins and endothelial dysfunction: molecular mechanisms and gene expression studies. <i>Future Lipidology</i> , 2007, 2, 119-122.	0.5	0
556	LDL-C REDUCTION AND GOAL ACHIEVEMENT IN PATIENTS WITH DIABETES, METABOLIC SYNDROME, OR NEITHER DISEASE, STRATIFIED BY NCEP CHD RISK CATEGORY. <i>Atherosclerosis Supplements</i> , 2008, 9, 73.	1.2	0
557	Response to Letter by Kotani et al. <i>Stroke</i> , 2008, 39, .	2.0	0
558	Therapy and clinical trials: new insights. <i>Current Opinion in Lipidology</i> , 2010, 21, 394-395.	2.7	0

#	ARTICLE	IF	CITATIONS
559	Lecithin:cholesterol acyltransferase and vascular disease. <i>Clinical Lipidology</i> , 2010, 5, 13-15.	0.4	0
560	Novel biotinylated bile acid amphiphiles: Micellar aggregates formation and interaction with hepatocytes. <i>Organic and Biomolecular Chemistry</i> , 2011, 9, 2899.	2.8	0
561	Corrigendum to "Treatment of diabetic ulcers, using autologous platelet and fibrin gel. Experience with the FIBRINETÁ® device" [Transf. Apher. Sci. 43 (2010) 171-172]. <i>Transfusion and Apheresis Science</i> , 2011, 44, 107.	1.0	0
562	PDB11 A Large-Scale Longitudinal Population-Based Study of Risk Reduction of Cardiovascular Complications in Patients on Bolus Insulin Analogues. <i>Value in Health</i> , 2012, 15, A495.	0.3	0
563	In Memoriam. Obituary: Professor Andrea Mezzetti, MD (1949-2013). <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2013, 23, 903-904.	2.6	0
564	Three-Year Health Care Expenditures in Diabetic Patients Receiving Rapid-Acting Insulin Analogues Versus Those on Human Regular Insulin. <i>Value in Health</i> , 2013, 16, A451.	0.3	0
565	Editorial (Hot Topic: Achieving Current Goals in Prevention and Treatment of Vascular Disease: An) <i>Tj ETQq1 1 0.784314 rgBT₀/Overlook</i>	1.9	0
566	Progression of early atherosclerotic vascular damage in patients with NAFLD and in controls of general population during 10 years of follow up. <i>Digestive and Liver Disease</i> , 2014, 46, e26.	0.9	0
567	Concluding comments. <i>Atherosclerosis Supplements</i> , 2014, 15, 52.	1.2	0
568	New strategies for the management of patients with homozygous familial hypercholesterolaemia. <i>Atherosclerosis Supplements</i> , 2014, 15, 17-18.	1.2	0
569	Epicardial fat thickness (EAT) in patients with nonalcoholic fatty liver disease (NAFLD) is associated with markers of cardiovascular damage and severity of steatosis. <i>Digestive and Liver Disease</i> , 2014, 46, e3-e4.	0.9	0
570	Proprotein convertase subtilisin/kexin type 9 deficient mice are protected from neointima formation in carotid artery injury model. <i>Atherosclerosis</i> , 2014, 235, e21-e22.	0.8	0
571	Epicardial and liver fat, evaluated by ultrasound in general population and in non-alcoholic fatty liver disease (NAFLD) predict cardiovascular damage. <i>Digestive and Liver Disease</i> , 2015, 47, e223.	0.9	0
572	Real-World Identification Of European Patients With Statin-Associated Symptoms: Clinical Practice Compared With Clinical Guidelines. <i>Value in Health</i> , 2015, 18, A401.	0.3	0
573	Medication persistence and the use of generic and brand-name blood pressure-lowering agents. <i>Journal of Hypertension</i> , 2015, 33, 2181.	0.5	0
574	Managing Patients With Statin-Associated Symptoms: Does Real-World Clinical Practice Align With Clinical Guidelines And Hta Recommendations In Europe?. <i>Value in Health</i> , 2015, 18, A401.	0.3	0
575	Drug interactions in pharmacovigilance. <i>Toxicology Letters</i> , 2015, 238, S28-S29.	0.8	0
576	Identification of two novel mutations of the LDL receptor gene in two Italian families with familial hypercholesterolemia. <i>Atherosclerosis</i> , 2015, 241, e114.	0.8	0

#	ARTICLE	IF	CITATIONS
577	Apolipoprotein E in humans and mice impacts the differentiation of naive CD4 T cells toward effector subsets. <i>Atherosclerosis</i> , 2015, 241, e7.	0.8	0
578	Epicardial fat thickness is an ectopic fat associated with metabolic syndrome, subclinical atherosclerosis and markers of cardiac dysfunction in the general population. <i>Atherosclerosis</i> , 2015, 241, e47.	0.8	0
579	Corrigendum to "Statins decrease thrombin generation in patients with hypercholesterolemia" [<i>Eur J Intern Med</i> 25(5), 449-451]. <i>European Journal of Internal Medicine</i> , 2015, 26, 460.	2.2	0
580	SAT0302...Active Systemic Lupus Erythematosus Associates with Carotid Intima-Media Thickness Progression. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 777.2-777.	0.9	0
581	Identification of Statin Intolerance: Results From A Survey of Clinicians in Taiwan. <i>Value in Health</i> , 2016, 19, A872.	0.3	0
582	Identification of Statin Intolerance: Results from a Survey of Clinicians in Six European Countries. <i>Value in Health</i> , 2016, 19, A664.	0.3	0
583	Identification and Management of Patients with Statin Intolerance in Saudi Arabia and the United Arab Emirates: Comparison of Results from a Clinician Survey. <i>Value in Health</i> , 2016, 19, A664.	0.3	0
584	Identification of Statin Intolerance: Results From A Survey of South Korean Clinicians. <i>Value in Health</i> , 2016, 19, A872.	0.3	0
585	Identification of Statin Intolerance: Results From a Survey of Clinicians in Japan. <i>Value in Health</i> , 2016, 19, A872-A873.	0.3	0
586	Management of Patients with Statin Intolerance: Results from a Survey of Clinicians in Six European Countries. <i>Value in Health</i> , 2016, 19, A664.	0.3	0
587	Identification and Management of Canadian Patients with Symptoms of Statin Intolerance: Results from a Real-World Clinical Practice Survey. <i>Value in Health</i> , 2016, 19, A53.	0.3	0
588	Pentraxin 3 deficiency is associated with increased arterial thrombosis in animal models. <i>Atherosclerosis</i> , 2016, 252, e250-e251.	0.8	0
589	Systemic lupus erythematosus flare-up is associated with increased 5-years carotid Intima-Media thickness progression. <i>Atherosclerosis</i> , 2016, 252, e169.	0.8	0
590	Identifying and Managing Patients with Symptoms of Statin Intolerance: Results from a Survey of Clinicians in the United States. <i>Value in Health</i> , 2016, 19, A53.	0.3	0
591	Reply to: "Statins probably do not cause cataracts". <i>Atherosclerosis</i> , 2016, 254, 311-312.	0.8	0
592	Role of PCSK9 (proprotein convertase subtilisin/kexin type 9) in obesity and metabolic syndrome: Beyond LDLR targeting. <i>Atherosclerosis</i> , 2016, 252, e223.	0.8	0
593	Identification and Management of Patients with Symptoms of Statin Intolerance: Results from A Survey of Brazilian Clinicians. <i>Value in Health</i> , 2016, 19, A53.	0.3	0
594	Impaired fatty acid synthesis affects immune cells activation: focus on sterol regulatory element binding factor-1c on T lymphocytes. <i>Atherosclerosis</i> , 2017, 263, e23.	0.8	0

#	ARTICLE	IF	CITATIONS
595	Influence of PCSK9 on biological behavior of mouse smooth muscle cells. <i>Atherosclerosis</i> , 2017, 263, e63.	0.8	0
596	Apolipoprotein E orchestrates T Naïve to T Effector memory cell polarization by modulating the crosstalk between systemic and immune cells lipid metabolism. <i>Atherosclerosis</i> , 2017, 263, e84.	0.8	0
597	Role of PCSK9 (proprotein convertase subtilisin/kexin type 9) beyond LDLR targeting: Focus on glucose metabolism. <i>Atherosclerosis</i> , 2017, 263, e102.	0.8	0
598	Characterization of metabolic syndrome in PLIC cohort. <i>Atherosclerosis</i> , 2017, 263, e181.	0.8	0
599	Effector memory T cells predict atherosclerosis progression and cardiovascular events over 4 years follow-up. <i>Atherosclerosis</i> , 2017, 263, e59.	0.8	0
600	Clinician interview results about the experiences of their patients who report side effects with statin treatment. <i>Atherosclerosis</i> , 2017, 263, e247.	0.8	0
601	Differential contribution of PCSK9 and LPL gene variants on lipid profile in the general population. <i>Atherosclerosis</i> , 2017, 263, e66.	0.8	0
602	Effect of PCSK9 loss-of-function mutation R46I on plasma lipids, endothelial function and vascular inflammation in the post-prandial state. <i>Atherosclerosis</i> , 2017, 263, e136.	0.8	0
603	PCSK9 inhibition in statin-intolerant HeFH patients: What's new?. <i>European Journal of Preventive Cardiology</i> , 2017, 24, 1525-1527.	1.8	0
604	Characterization of Italian patients with familial hypercholesterolemia: The lipigen study. <i>Atherosclerosis</i> , 2017, 263, e235.	0.8	0
605	Corrigendum to "Incretin-based drugs and risk of acute pancreatitis: A nested-case control study within a healthcare database" [Diabetes Res. Clin. Pract. 108 (2) (2015) 243-249]. <i>Diabetes Research and Clinical Practice</i> , 2017, 125, 68.	2.8	0
606	The long pentraxin 3 (PTX3) plays a key role in the immunomodulation of diet induced-obesity in mice. <i>Atherosclerosis</i> , 2018, 275, e16.	0.8	0
607	The PCSK9/LDLR axis impacts insulin secretion and glucose response. <i>Atherosclerosis</i> , 2018, 275, e55.	0.8	0
608	Familial Hypercholesterolemia. , 2018, , 285-297.		0
609	Coronary disease prevention: towards a more personalised approach. <i>European Journal of Preventive Cardiology</i> , 2018, 25, 1884-1886.	1.8	0
610	Multilevel models to estimate standard intima-media thickness curves for individual cardiovascular risk evaluation. <i>Atherosclerosis</i> , 2018, 275, e67.	0.8	0
611	Clinical and genetic features of familial hypercholesterolemia in pediatric patients: The lipigen Study. <i>Atherosclerosis</i> , 2018, 275, e98-e99.	0.8	0
612	PCSK9 Deficiency Reduces Insulin Secretion and Promotes Glucose Intolerance: the Role of the LDL Receptor. <i>Atherosclerosis Supplements</i> , 2018, 32, 21.	1.2	0

#	ARTICLE	IF	CITATIONS
613	Impact of PCSK9 on human-IPSC derived cardiomyocyte mitochondrial function and metabolism. <i>Atherosclerosis</i> , 2020, 315, e86.	0.8	0
614	Bempedoic Acid Efficacy and Safety in High CVD Risk Patients Treated With or Without Ezetimibe: Pooled Analysis of 4 Phase 3 Clinical Trials. <i>Journal of Clinical Lipidology</i> , 2020, 14, 569-570.	1.5	0
615	Factors that Influence Bempedoic Acid-Mediated Reductions in High-sensitivity C reactive Protein: Analysis of Pooled Patient-level Data from Phase 3 Clinical Trials. <i>Journal of Clinical Lipidology</i> , 2020, 14, 577.	1.5	0
616	Safety, Tolerability, and Pharmacokinetics of Evinacumab, an Angiopoietin-Like Protein 3 Inhibitor, in Healthy Japanese and Caucasian Subjects. <i>Journal of Clinical Lipidology</i> , 2020, 14, 581.	1.5	0
617	Efficacy and Safety of Bempedoic Acid in Elderly Patients: Pooled Analyses from Phase 3 Trials. <i>Journal of Clinical Lipidology</i> , 2020, 14, 583.	1.5	0
618	Clinical decision support system for lipid metabolism disorders: relevance and potential. <i>Russian Journal of Cardiology</i> , 2021, 26, 4539.	1.4	0
619	Hyperglycemic condition mimics tgrls lipid accumulation in cardiomyocytes derived from human-IPSCS. <i>Atherosclerosis</i> , 2021, 331, e124.	0.8	0
620	Cardiovascular immune-inflammatory markers and cellular aging in the general population. <i>Atherosclerosis</i> , 2021, 331, e35.	0.8	0
621	Adoptive transfer of CX3CR1 transduced-T regulatory cells improves homing to the atherosclerotic plaques and dampens atherosclerosis progression. <i>Atherosclerosis</i> , 2021, 331, e33.	0.8	0
622	Observational multicenter study on effectiveness and tolerability of alirocumab in real world, The Omero study: Interim data from the fist 352 participants. <i>Atherosclerosis</i> , 2021, 331, e166.	0.8	0
623	Targeting Two Sources of Cholesterol – An Advanced Treatment Approach to Lipid-lowering Management. <i>European Cardiology Review</i> , 2005, 1, 1.	2.2	0
624	Knowledge-Based Governance Can Improve the Elderly Population's Equity of Access to Public Pharmaceutical Funding: The ASSET (Age/Sex Standardised Estimates of Treatment) Research Model. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
625	Cholesterol Absorption Inhibitors. , 2009, , 288-297.		0
626	Pentraxins and Atherosclerosis. , 2012, , 219-237.		0
627	Activation of Lipoprotein Lipase by Synthetic Fragments of ApoC-II. , 1980, , 397-400.		0
628	Abnormalities of Apolipoprotein B Metabolism in the Lipid Clinic. , 1991, , 79-89.		0
629	Defective Catabolism of Oxidized LDL by J774 Murine Macrophages. <i>Medical Science Symposia Series</i> , 1993, , 427-439.	0.0	0
630	Causes Underlying the Reduced Response to Simvastatin Treatment in Hypercholesterolemic Patients. , 1993, , 207-229.		0

#	ARTICLE	IF	CITATIONS
631	Fibrates: Modes of Action. Medical Science Symposia Series, 1995, , 295-306.	0.0	0
632	Oxidized Ldl Trigger the Expression of Hsp70 in Cultured Endothelial Cells. Medical Science Symposia Series, 1996, , 603-612.	0.0	0
633	An acidic microenvironment sets the humoral pattern recognition molecule PTX3 in a tissue repair mode. Journal of Cell Biology, 2015, 209, 20940IA93.	5.2	0
634	OBSOLETE: Familial Hypercholesterolemia. , 2018, , .		0
635	Abstract 14248: Efficacy and Safety of Bempedoic Acid in Patients Who Cannot Tolerate Statins: Pooled Analysis of 4 Phase 3 Clinical Trials. Circulation, 2020, 142, .	1.6	0
636	Abstract 13130: Efficacy and Safety of Bempedoic Acid by Sex: Pooled Analyses From Phase 3 Trials. Circulation, 2020, 142, .	1.6	0
637	The Association of Proprotein Convertase Subtilisin/Kexin Type 9 to Plasma Low-Density Lipoproteins: An Evaluation of Different Methods. Metabolites, 2021, 11, 861.	2.9	0
638	341 Observational multicentre study on effectiveness and tolerability of Alirocumab in real world, the OMERO study: interim data from the first 699 patients. European Heart Journal Supplements, 2021, 23, .	0.1	0
639	Interleukin 1 receptor 8 deficiency does not impact atherosclerosis. Thrombosis and Haemostasis, 2022, 0, .	3.4	0
640	Formation of high density lipoprotein-like particles from chylomicrons. Research in Clinic and Laboratory, 1982, 12, 51-62.	0.3	0